<SEC-DOCUMENT>0001047469-18-005006.txt : 20180712
<SEC-HEADER>0001047469-18-005006.hdr.sgml : 20180712
<ACCEPTANCE-DATETIME>20180712163037
ACCESSION NUMBER:		0001047469-18-005006
CONFORMED SUBMISSION TYPE:	S-3ASR
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20180712
DATE AS OF CHANGE:		20180712
EFFECTIVENESS DATE:		20180712

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptimmune Therapeutics PLC
		CENTRAL INDEX KEY:			0001621227
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3ASR
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-226147
		FILM NUMBER:		18950750

	BUSINESS ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX
		BUSINESS PHONE:		44 1235 430000

	MAIL ADDRESS:	
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RX

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptimmune Ltd
		DATE OF NAME CHANGE:	20141001
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3ASR
<SEQUENCE>1
<FILENAME>a2236188zs-3asr.htm
<DESCRIPTION>S-3ASR
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg49801_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>As filed with the Securities and Exchange Commission on July&nbsp;12, 2018  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B> Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><B><BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><B> <div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=1><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>FORM S-3<BR>  </B></FONT><FONT SIZE=1><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF&nbsp;1933  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>ADAPTIMMUNE THERAPEUTICS&nbsp;PLC<BR>  </B></FONT><FONT SIZE=1>(Exact name of registrant as specified in its charter) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>England and Wales</B></FONT><FONT SIZE=1><BR>
(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> Not Applicable</B></FONT><FONT SIZE=1><BR>
(I.R.S. Employer<BR>
Identification No.)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>60 Jubilee Avenue, Milton Park<BR>
Abingdon, Oxfordshire OX14&nbsp;4RX<BR>
United Kingdom<BR>
(44) 1235 430000</B></FONT><FONT SIZE=1><BR>
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>ADAPTIMMUNE&nbsp;LLC<BR>
351 Rouse Boulevard, The Navy Yard<BR>
Philadelphia, PA 19112<BR>
United States of America<BR>
(215)&nbsp;825 9260</B></FONT><FONT SIZE=1><BR>
(Name, address, including zip code, and telephone number, including area code, of agent for service) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Please send copies of all communications to:</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=1><B>David S. Bakst, Esq.<BR>
Mayer Brown&nbsp;LLP<BR>
1221 Avenue of the Americas<BR>
New York, New York 10020<BR>
Telephone: (212)&nbsp;506-2500<BR>
Facsimile: (212)&nbsp;262-1910</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=1><B> James J. Noble, Chief Executive Officer<BR>
Adrian Rawcliffe, Chief Financial Officer<BR>
Adaptimmune Therapeutics&nbsp;plc<BR>
60 Jubilee Avenue, Milton Park<BR>
Abingdon, Oxfordshire, OX14&nbsp;4RX<BR>
United Kingdom<BR>
Telephone: (44)&nbsp;1235 430000<BR>
Facsimile: (44)&nbsp;1235 430001</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Approximate date of commencement of proposed sale to the public:<BR>
From time to time after the effective date of this registration statement.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following
box:&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier effective registration statement for the same offering:&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering:&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is a registration statement pursuant to General Instruction&nbsp;I.D. or a post-effective amendment thereto that shall become effective upon filing
with the Commission pursuant to Rule&nbsp;462(e) under the Securities Act, check the following box:&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction&nbsp;I.D. filed to register additional securities
or additional classes of securities pursuant to Rule&nbsp;413(b) under the Securities Act, check the following box:&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the
definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule&nbsp;12b-2 of the Exchange Act. (Check one): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="102pt" style="font-family:times;"></TD>
<TD WIDTH="12%" style="font-family:times;"></TD>
<TD WIDTH="79pt" style="font-family:times;"></TD>
<TD WIDTH="12%" style="font-family:times;"></TD>
<TD WIDTH="98pt" style="font-family:times;"></TD>
<TD WIDTH="12%" style="font-family:times;"></TD>
<TD WIDTH="120pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Large&nbsp;accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Non-accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT><BR></FONT> <FONT SIZE=1>(Do not check if a<BR>
smaller reporting company)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;text-align:center;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"text-align:center;" -->


 Smaller&nbsp;reporting&nbsp;company&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></font> <p align=center style="font-family:times;margin-top:0pt;margin-left:0pt;"> <FONT SIZE=1> Emerging growth company&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>CALCULATION OF REGISTRATION FEE  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="30%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Title of Each Class of Securities<BR>
to be Registered</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount to be<BR>
Registered</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed Maximum<BR>
Offering Price per<BR>
Share</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed Maximum<BR>
Aggregate Offering<BR>
Price</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount of<BR>
Registration Fee</B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1><B> </B></FONT><FONT SIZE=1>Ordinary shares, nominal value &pound;0.001 per share(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> (1)(2)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(1)(2)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(1)(2)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(3)</B></FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Omitted
pursuant to General Instructions&nbsp;II.E of Form&nbsp;S-3 under the Securities Act of 1933, as amended, or the Securities Act.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>There
are being registered hereunder such indeterminate number or amount of ordinary shares as may from time to time be issued at indeterminate prices. Pursuant to
Rule&nbsp;416 under the Securities Act, the securities being registered hereunder include such indeterminate number of securities as may be issuable with respect to the securities being registered
hereunder as a result of share splits, share dividends or similar transactions.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>In
reliance on, and in accordance with, Rules&nbsp;456(b) and 457(r) under the Securities Act, the registrant is deferring payment of all applicable registration
fees.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
ordinary shares registered hereby will be represented by American Depositary Shares ("ADSs"), each of which will represent six ordinary shares of the registrant.
Such ADSs issuable on deposit of the ordinary shares registered hereby have been registered under two separate registration statements on Form&nbsp;F-6 (File No.: 333-203642 and File No.:
333-212714).  </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=1><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall
file&nbsp;a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or
until the Registration Statement shall become effective on such date as the U.S. Securities and Exchange Commission acting pursuant to said Section&nbsp;8(a), may determine.  </B></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=1>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:times;"><FONT SIZE=1><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=568575,FOLIO='blank',FILE='DISK133:[18ZBZ1.18ZBZ49801]BA49801A.;17',USER='JTAYLORA',CD='10-JUL-2018;10:22' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bb49801_explanatory_note"> </A>
<A NAME="toc_bb49801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPLANATORY NOTE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Registration Statement is a "shelf" registration statement and relates to ordinary shares represented by ADSs that we may offer from time
to time. This Registration Statement contains a form of base prospectus that will be used in connection with offerings of the ADSs, if and when such offerings are made. The specific terms of any
offering of ADSs will be set forth in a prospectus supplement relating to such securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the date of this Registration Statement, we are currently eligible to offer securities under the Registration Statement on Form&nbsp;S-3 filed with the Securities and Exchange
Commission on July&nbsp;28, 2016, as amended, and declared effective on September&nbsp;12, 2016, or the Existing S-3. The Existing S-3 will expire and no longer be available for use by us on
September&nbsp;12, 2019. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=660872,FOLIO='blank',FILE='DISK133:[18ZBZ1.18ZBZ49801]BB49801A.;3',USER='JTAYLORA',CD='10-JUL-2018;10:22' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g203469.jpg" ALT="LOGO" WIDTH="561" HEIGHT="91">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>American Depositary Shares representing Ordinary Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may offer and sell from time to time up to an indeterminate number of our ordinary shares in the form of American Depositary Shares, or ADSs,
of Adaptimmune Therapeutics&nbsp;plc. Each ADS represents six ordinary shares, par value &pound;0.001 per share. The specific terms of the ADSs to be offered, and any other information
relating to a specific offering, will be set forth in a supplement to this prospectus or in one or more documents incorporated by reference in this prospectus. You should carefully read this
prospectus and the applicable prospectus supplement, as well as the documents incorporated or deemed to be incorporated by reference in this prospectus, before you purchase any of the ADSs offered
hereby. This prospectus may not be used to sell these ADSs without a supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may offer ADSs from time to time in amounts, at prices and on other terms to be determined at the time of offering. We may offer and sell ADSs to or through one or more underwriters,
dealers and agents or directly to purchasers, on a continuous or delayed basis. The names of any underwriters, dealers or agents involved in the sale of any ADSs and the specific manner in which they
may be offered, including any applicable purchase price, fee, commission or discount arrangement between or among them, will be set forth in the prospectus supplement covering the sale of those ADSs.
See "Plan of Distribution." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
ADSs are listed on The Nasdaq Global Select Market under the symbol "ADAP." On July&nbsp;11, 2018, the closing price of our ADSs on The Nasdaq Global Select Market was $10.91. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Investing in our ADSs involves risks. See "Risk Factors" on page&nbsp;4 of this prospectus and any similar section contained in the applicable prospectus
supplement concerning factors you should consider before investing in our ADSs.</B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or
adequacy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>The date of this prospectus is July&nbsp;12, 2018.  </B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=716845,FOLIO='blank',FILE='DISK133:[18ZBZ1.18ZBZ49801]BC49801A.;8',USER='MKEANE',CD='11-JUL-2018;16:37' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bg49801_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG49801A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg49801_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG49801_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#bi49801_prospectus_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROSPECTUS SUMMARY</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#bi49801_prospectus_summary"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#bk49801_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#bk49801_forward-looking_statements"><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da49801_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da49801_risk_factors"><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da49801_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da49801_use_of_proceeds"><FONT SIZE=2>5</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da49801_description_of_share_capital"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF SHARE CAPITAL</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da49801_description_of_share_capital"><FONT SIZE=2>6</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de49801_description_of_american_depositary_shares"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF AMERICAN DEPOSITARY SHARES</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de49801_description_of_american_depositary_shares"><FONT SIZE=2>26</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg49801_plan_of_distribution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg49801_plan_of_distribution"><FONT SIZE=2>37</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di49801_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di49801_legal_matters"><FONT SIZE=2>40</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di49801_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di49801_experts"><FONT SIZE=2>40</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di49801_service_of_process_and_enforcement_of_judgments"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SERVICE OF PROCESS AND ENFORCEMENT OF JUDGMENTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di49801_service_of_process_and_enforcement_of_judgments"><FONT SIZE=2>40</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di49801_incorporation_by_reference"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION BY REFERENCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di49801_incorporation_by_reference"><FONT SIZE=2>40</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di49801_where_you_can_find_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di49801_where_you_can_find_more_information"><FONT SIZE=2>41</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=501483,FOLIO='i',FILE='DISK133:[18ZBZ1.18ZBZ49801]BG49801A.;6',USER='JTAYLORA',CD='10-JUL-2018;10:49' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bi49801_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bi49801_prospectus_summary"> </A>
<A NAME="toc_bi49801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is part of an "automatic shelf" registration statement that we filed with the Securities and Exchange Commission, which we refer
to as the "SEC", as a "well-known seasoned issuer" as defined in Rule&nbsp;405 of the Securities Act utilizing a "shelf" registration process. Under this shelf registration process, we may, over
time, offer and sell the securities described in this prospectus in one or more offerings as described in this prospectus. This prospectus provides you with a general description of the securities
that may be offered. Each time we offer securities under this prospectus, we will provide a prospectus supplement or other offering materials that will contain specific information about the terms of
that offering. We may also add, update or change information contained in this prospectus by means of a prospectus supplement or by incorporating by reference information that we file or furnish to
the SEC. The registration statement that we filed with the SEC includes exhibits that provide more detail on the matters discussed in this prospectus. If the information in this prospectus is
inconsistent with a prospectus supplement, you should rely on the information in that prospectus supplement. Please carefully read this prospectus and any prospectus supplement, together with the
additional information described under the headings "Where You Can Find More Information" and "Incorporation by Reference," before purchasing any securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should rely only on the information contained or incorporated by reference in this prospectus, any prospectus supplement and any issuer free writing prospectus. "Incorporated by
reference" means that we can disclose important information to you by referring you to another document filed separately with the SEC. We have not authorized any other person to provide you with
different information. If anyone provides you with different information, you should not rely on it. We are not making an offer of these securities in any state or jurisdiction where the offer is not
permitted. You should only assume that the information in this prospectus or in any prospectus supplement or issuer free writing prospectus is accurate only as of their respective dates. Our business,
financial condition, results of operations and prospects may have changed since those dates. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Company  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company's
unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune is currently conducting
clinical trials with SPEAR T-cells targeting MAGE-A4, MAGE-A10, and alpha fetoprotein, or AFP, across several solid tumor indications. GlaxoSmithKline&nbsp;plc (LSE:GSK) (NYSE:GSK) exercised its
option to exclusively license the right to research, develop, and commercialize Adaptimmune's NY-ESO SPEAR T-cell therapy program in September 2017. Transition of this program to GSK is ongoing.
Adaptimmune has over 350 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
this prospectus, "Adaptimmune," "the "Company," "we," "us" and "our" refer to Adaptimmune Therapeutics&nbsp;plc and its consolidated subsidiaries, except where the context otherwise
requires. "Adaptimmune&reg;" and "SPEAR&reg;" are registered trademarks of Adaptimmune. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our registered and principal executive offices are located at 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14&nbsp;4RX, United
Kingdom; our general telephone number is (44)&nbsp;1235&nbsp;430000; and our internet address is </FONT><FONT SIZE=2><I>http://www.adaptimmune.com</I></FONT><FONT SIZE=2>. Our website and the
information contained on or accessible through our website are not part of this prospectus. Our agent for service of process in the United States is our subsidiary, Adaptimmune&nbsp;LLC, 351 Rouse
Boulevard, The Navy Yard, Philadelphia PA 19112. Since May&nbsp;6, 2015, our ADSs, which each represent 6 ordinary shares, have been listed on The Nasdaq Global Select Market, or Nasdaq, under the
symbol "ADAP." </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=340092,FOLIO='1',FILE='DISK133:[18ZBZ1.18ZBZ49801]BI49801A.;7',USER='MTITUSS',CD='10-JUL-2018;10:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bk49801_1_2"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bk49801_forward-looking_statements"> </A>
<A NAME="toc_bk49801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus, the financial statements and other documents that we incorporate by reference in this prospectus and any related prospectus
supplement may contain forward-looking statements that are based on our current expectations, assumptions, estimates and projections about us and our industry. All statements other than statements of
historical fact in this prospectus, the financial statements and other documents that we incorporate by reference in this prospectus and any related prospectus supplement are forward-looking
statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that could cause our actual results of operations, financial
condition, liquidity, performance, prospects, opportunities, achievements or industry results, as well as those of the markets we serve or intend to serve, to differ materially from those expressed
in, or suggested by, these forward-looking statements. These forward-looking statements are based on assumptions regarding our present and future business strategies and the environment in which we
expect to operate in the future.
Important factors that could cause those differences include, but are not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to successfully advance our MAGE-A10, MAGE-A4 and AFP SPEAR T-cells through clinical development and the timing within which we can
recruit patients and treat patients in our clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to successfully and reproducibly manufacture SPEAR T-cells in order to meet patient demand; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to further develop our commercial manufacturing process for our SPEAR T-cells, transfer such commercial process to third party
contract manufacturers, if required, and for such third party contract manufacturers or ourselves to manufacture SPEAR T-cells to the quality and on the timescales we require; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope and timing of performance of our ongoing collaboration with GSK and the scope and timing of transition of the NY-ESO SPEAR T-cell
program to GSK following exercise of option by GSK; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to successfully advance our SPEAR T-cell technology platform to improve the safety and effectiveness of our existing SPEAR T-cell
candidates and to submit Investigational New Drug Applications, or INDs, for new SPEAR T-cell candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the rate and degree of market acceptance of T-cell therapy generally, and of our SPEAR T-cells; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> government regulation and approval, including, but not limited to, the expected regulatory approval timelines for our SPEAR T-cells and the
level of pricing and reimbursement for our SPEAR T-cells, if approved for marketing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the existence of any third party patents preventing further development of any of our SPEAR T-cells, including, any inability to obtain
appropriate third party licenses, or enforcement of patents against us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to obtain granted patents covering our SPEAR T-cells and to enforce such patents against third parties; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> volatility in equity markets in general and in the biopharmaceutical sector in particular; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> fluctuations in the price of materials and bought-in components; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our relationships with suppliers, contract manufacturing organizations or CROs and other third-party providers including fluctuations in the
price of materials and services, ability to obtain reagents particularly where such reagents are only available from a single source, and performance of third party providers; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=6,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=626264,FOLIO='2',FILE='DISK133:[18ZBZ1.18ZBZ49801]BK49801A.;3',USER='JTAYLORA',CD='10-JUL-2018;10:22' -->
<A NAME="page_bk49801_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> increased competition from other companies in the biotechnology and pharmaceutical industries including where such competition impacts ability
to recruit patients in to clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> claims for personal injury or death arising from the use of our SPEAR T-cell candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to attract and retain qualified personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a change in our status as an emerging growth company under the Jumpstart Our Business Start-ups Act of 2012, or JOBS Act; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> additional factors that are not known to us at this time. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional
factors that could cause actual results, financial condition, liquidity, performance, prospects, opportunities, achievements or industry results to differ materially include,
but are not limited to, those discussed under "Risk Factors" in Part&nbsp;II, Item&nbsp;1A of our Quarterly Report on Form&nbsp;10-Q for the period ended March&nbsp;31, 2018, which is
incorporated by reference herein, as updated by our other SEC filings filed after such Quarterly Report. Additional risks that we may currently deem immaterial or that are not presently known to us
could also cause the forward-looking events discussed in this prospectus not to occur. Additional risks that we may currently deem immaterial or that are not presently known to us could also cause the
forward-looking events discussed in this prospectus not to occur. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect" and similar words are intended to
identify estimates and forward-looking statements. Estimates and forward-looking statements speak only at the date they were made, and we undertake no obligation to update or to review any estimate
and/or forward-looking statement because of new information, future events or other factors. Estimates and forward-looking statements involve risks and uncertainties and are not guarantees of future
performance. Our future results may differ materially from those expressed in these estimates and forward-looking statements. In light of the risks and uncertainties described above, the estimates and
forward-looking statements discussed in this prospectus, the documents that we incorporate by reference in this prospectus and any related prospectus supplement might not occur, and our future results
and our performance may differ materially from those expressed in such forward-looking statements due to, inclusive of, but not limited to, the factors mentioned above.
Because of these uncertainties, you should not make any investment decision based on these estimates and forward-looking statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=7,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=469835,FOLIO='3',FILE='DISK133:[18ZBZ1.18ZBZ49801]BK49801A.;3',USER='JTAYLORA',CD='10-JUL-2018;10:22' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da49801_1_4"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da49801_risk_factors"> </A>
<A NAME="toc_da49801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before making an investment decision, you should carefully consider the risks described under "Risk Factors" in the applicable prospectus
supplement, together with all of the other information appearing in this prospectus or incorporated by reference into this prospectus and any applicable prospectus supplement, in light of your
particular investment objectives and financial circumstances. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. The trading price
of our securities could decline due to any of these risks, and you may lose all or part of your investment. This prospectus and the incorporated documents also contain forward-looking statements that
involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks mentioned
elsewhere in this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=8,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=33922,FOLIO='4',FILE='DISK133:[18ZBZ1.18ZBZ49801]DA49801A.;9',USER='NDEWIND',CD='10-JUL-2018;09:57' -->
<A NAME="page_da49801_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da49801_use_of_proceeds"> </A>
<A NAME="toc_da49801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will retain broad discretion over the use of the net proceeds from the sale of our ADSs offered by us under this prospectus. Except as
described in any prospectus supplement, we currently anticipate using the net proceeds from the sale of our ADSs offered hereby primarily for working capital and other general corporate purposes which
include, but are not limited to, funding research and development and, if approved, the commercialization of our product candidates and to discover additional product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=9,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=785370,FOLIO='5',FILE='DISK133:[18ZBZ1.18ZBZ49801]DA49801A.;9',USER='NDEWIND',CD='10-JUL-2018;09:57' -->
<A NAME="page_da49801_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da49801_description_of_share_capital"> </A>
<A NAME="toc_da49801_3"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF SHARE CAPITAL    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The following summary describes our share capital, the material provisions of our articles of association, and
applicable provisions of the U.K. Companies Act 2006 (the "Companies Act 2006"). Because the following is only a summary, it does not contain all of the information that may be important to you. For a
complete description, you should refer to our articles of association, a copy of which has been previously filed.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We were incorporated pursuant to the laws of England and Wales as Adaptimmune Therapeutics Limited in December 2014 to become a holding company
for
Adaptimmune Limited. Pursuant to the terms of a corporate reorganization the first stage of which was completed on February&nbsp;23, 2015, all of the issued share capital in Adaptimmune Limited was
exchanged for identical shares in Adaptimmune Therapeutics Limited and, as a result, Adaptimmune Limited became a wholly owned subsidiary of Adaptimmune Therapeutics Limited. On March&nbsp;20, 2015,
all holders of options over ordinary shares of Adaptimmune Limited exchanged each of their options for equivalent options over ordinary shares of Adaptimmune Therapeutics Limited. On April&nbsp;1,
2015, we re-registered Adaptimmune Therapeutics Limited as a public limited company and changed the company's name to Adaptimmune Therapeutics&nbsp;plc. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are registered with the Registrar of Companies in England and Wales under number&nbsp;9338148 and our registered office is at 60 Jubilee Avenue, Milton Park, Oxfordshire
OX14&nbsp;4RX, United Kingdom. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
our corporate reorganization, certain resolutions were passed by our shareholders on April&nbsp;27, 2015. These included resolutions for the adoption of new articles of
association that became effective upon the admission of our ADSs to trading on Nasdaq on May&nbsp;6, 2015, and which articles of association were amended by special resolution passed on
June&nbsp;16, 2016. See "&#151;Key Provisions of Our Articles of Association." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
other resolutions were passed by our shareholders at our third annual general meeting on June&nbsp;21, 2017. These included resolutions
for:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The general authorization of our directors for the purpose of s551 Companies Act 2006 to issue new ordinary shares in the Company and grant
rights to subscribe for or convert any securities into ordinary shares in the Company up to a maximum aggregate nominal amount of &pound;140,000.00 for a period of five years from the date of
the resolution and expiring on June&nbsp;20, 2022. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The empowering of our directors pursuant to s570(1) Companies Act 2006 to issue equity securities for cash pursuant to the s551 authority
referred to above as if the statutory pre-emption rights under s561(1) Companies Act 2006 did not apply to such allotments for a period commencing on the date of the resolution and expiring on the
conclusion of the annual general meeting of the Company to be held in 2019. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Issued Share Capital  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our issued share capital as of July&nbsp;11, 2018 was 566,496,400 ordinary shares with a par value of &pound;0.001 per ordinary share.
Each issued ordinary share is fully paid. We currently have no deferred shares in our issued share capital. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=10,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=913383,FOLIO='6',FILE='DISK133:[18ZBZ1.18ZBZ49801]DA49801A.;9',USER='NDEWIND',CD='10-JUL-2018;09:57' -->
<A NAME="page_da49801_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ordinary Shares  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our ordinary shares have the rights and restrictions described in "&#151;Key Provisions of Our Articles of Association." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of July&nbsp;11, 2018, there were options to purchase 88,772,642 ordinary shares outstanding. All options granted are exercisable at the share price on or around the date of the
grant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
vesting periods for options granted through July&nbsp;11, 2018 are: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options granted in 2009:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100% on the third anniversary of the grant date</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options granted in 2011, 2012, 2013 and April 2014:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25% on the first anniversary and 75% in annual installments over the following three years</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options granted in December 2014:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25% on the first anniversary and 75% in monthly installments over the following three years</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options granted in March 2015:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25% on the first anniversary and 75% in monthly installments over the following three years</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options granted in May 2015:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25% on the first anniversary and 75% in monthly installments over the following three years, except for options granted to Non-Executive Directors which all vested immediately</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options granted in January and April 2016:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25% on the first anniversary and 75% in monthly installments over the following three years</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options granted in June 2016:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25% on the first anniversary and 75% in monthly installments over the following two years (granted to a Non-Executive Director)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options granted in August 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25% on the first anniversary and 75% in monthly installments over the following three years, except for options granted to Non-Executive Directors which all vested on the first anniversary of the grant
date.</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options granted in November 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25% on the first anniversary and 75% in monthly installments over the following two years (granted to Non-Executive Directors).</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options granted in December 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25% on the first anniversary and 75% in monthly installments over the following three years.</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options granted in January, March and April 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25% on the first anniversary and 75% in monthly installments over the following three years.</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options granted in July 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25% on the first anniversary and 75% in monthly installments over the following three years, except for options granted to Non-Executive Directors which all vested on the first anniversary of the grant
date.</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options granted in October 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25% on the first anniversary and 75% in monthly installments over the following three years.</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options granted in January 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25% on the first anniversary and 75% in monthly installments over the following three years, except for RSU-style options which will vest as to 25% on the first anniversary and 75% in annual installments
over the following three years.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=11,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=849844,FOLIO='7',FILE='DISK133:[18ZBZ1.18ZBZ49801]DA49801A.;9',USER='NDEWIND',CD='10-JUL-2018;09:57' -->
<A NAME="page_da49801_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options granted in April 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25% on the first anniversary and 75% in monthly installments over the following three years.</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options granted in June 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100% on the first anniversary of the grant date (granted to Non-Executive Directors).</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options granted in July 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25% on the first anniversary and 75% in monthly installments over the following three years, except for options granted to a Non-Executive Director which will vest as to 25% on the first anniversary and
75% in monthly installments over the following two years.</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All options lapse after 10&nbsp;years from the date of grant.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preferred Shares  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may, from time to time, following an ordinary resolution of the ordinary shareholders granting authority to the directors
to allot shares and special resolution of the ordinary shareholders to amend the articles of association (and disapply pre-emption rights, if not already disapplied), direct the issuance of preferred
shares in series and may, at the time of issuance, determine the designations, powers, preferences, privileges, and relative participating, optional or special rights as well as the qualifications,
limitations or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights of
the ordinary shares. Holders of preferred shares may be entitled to receive a preference payment in the event of our liquidation before any payment is made to the holders of ordinary shares. There are
currently no preferred shares outstanding, and we have no present intention to issue any preferred shares. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Key Provisions of Our Articles of Association  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The following is a summary of certain key provisions of our articles of association. Please note that this is only a
summary and is not intended to be exhaustive. For further information please refer to the full version of our articles of association, which is included as an exhibit to the registration statement of
which this prospectus is a part</I></FONT><FONT SIZE=2>. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Shares and Rights Attaching to Them  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All ordinary shares have the same rights and rank </FONT><FONT SIZE=2><I>pari passu</I></FONT><FONT SIZE=2> in all respects. Subject to the
provisions of the Companies Act 2006 and any other relevant legislation, our shares may be issued with such preferred, deferred or other rights, or such restrictions, whether in relation to dividends,
returns of capital, voting or otherwise, as we may determine by ordinary resolution (or, failing any such determination, as the directors may determine). </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting Rights  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to any other provisions of our articles of association and without prejudice to any special rights, privileges or restrictions as to
voting attached to any shares forming part of our share capital, the voting rights of shareholders are as follows. On a show of hands, each shareholder present in person, and each duly authorized
representative present in person of a shareholder that is corporation, has one vote. On a show of hands, each proxy present in person who has been duly appointed by one or more shareholders has one
vote, but a proxy has one vote for and one vote against a resolution if, in certain circumstances, the proxy is instructed by more than one shareholder to vote in different ways on </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=12,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=153770,FOLIO='8',FILE='DISK133:[18ZBZ1.18ZBZ49801]DA49801A.;9',USER='NDEWIND',CD='10-JUL-2018;09:57' -->
<A NAME="page_da49801_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>a
resolution. On a poll, each shareholder present in person or by proxy or (being a corporation) by a duly authorized representative has one vote for each share held by the shareholder. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are prohibited (to the extent specified by the Companies Act 2006) from exercising any rights to attend or vote at meetings in respect of any shares held by us as treasury shares. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restrictions on Voting Where Sums Overdue on Shares  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of our shareholders (whether present in person by proxy or, in the case of a corporate member, by a duly authorized representative) shall
(unless the directors otherwise determine) be entitled to vote at any general meeting or at any separate class meeting in respect of any share held by him unless all calls or other sums payable by him
in respect of that share have been paid. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Calls on Shares  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The directors may from time to time make calls on shareholders in respect of any moneys unpaid on their shares, whether in respect of the
nominal value of the shares or by way of premium. Shareholders are required to pay called amounts on shares subject to receiving at least 14 clear days' notice specifying the time and place for
payment. If a shareholder fails to pay any part of a call, the directors may serve further notice naming another day not being less than 14 clear days from the date of the further notice requiring
payment and stating that in the event of non-payment the shares in respect of which the call was made will be liable to be forfeited. Subsequent forfeiture requires a resolution by the directors. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the Companies Act 2006 and the provisions of all other relevant legislation, we may by ordinary resolution declare dividends in
accordance with the respective rights of shareholders but no such dividend shall exceed the amount recommended by the directors. If, in the opinion of the directors, our profits available for
distribution justify such payments, the directors may pay fixed dividends payable on any of our shares with preferential rights, half-yearly or otherwise, on fixed dates and from time to time pay
interim dividends to the holders of any class of shares. Subject to any special rights attaching to or terms of issue of any shares, all dividends shall be declared and paid according to the amounts
paid up on the shares on which the dividend is paid. No dividend shall be payable to us in respect of any shares held by us as treasury shares (except to the extent permitted by the Companies Act 2006
and any other relevant legislation). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may, upon the recommendation of the directors, by ordinary resolution, direct payment of a dividend wholly or partly by the distribution of specific assets. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
dividends unclaimed may be invested or otherwise used at the directors' discretion for our benefit until claimed (subject as provided in the articles of association), and all
dividends unclaimed after a period of 12&nbsp;years from the date when such dividend became due for payment shall be forfeited and shall revert to us. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
directors may, if so authorized by ordinary resolution passed at any general meeting, offer any holders of the ordinary shares the right to elect to receive in lieu of that dividend
an allotment of ordinary shares credited as fully paid. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may cease to send any check or warrant by mail or may stop the transfer of any sum by any bank or other funds transfer system for any dividend payable on any of our shares, which is
normally paid in that manner on those shares if in respect of at least two consecutive dividends the checks or warrants have been returned undelivered or remain uncashed or the transfer has failed and
reasonable inquiries made by us have failed to establish any new address of the holder. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=13,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=74645,FOLIO='9',FILE='DISK133:[18ZBZ1.18ZBZ49801]DA49801A.;9',USER='NDEWIND',CD='10-JUL-2018;09:57' -->
<A NAME="page_da49801_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
or the directors may specify a "record date" on which persons registered as the holders of shares shall be entitled to receipt of any dividend. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Distribution of Assets on Winding-up  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to any special rights attaching to or the terms of issue of any shares, on any winding-up of the Company our surplus assets remaining
after satisfaction of our liabilities will be distributed among our shareholders in proportion to their respective holdings of shares and the amounts paid up on those shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
any winding-up of the Company (whether the liquidation is voluntary, under supervision or by the Court, the liquidator may with the authority of a special resolution of the Company
and any other sanction required by any relevant legislation, divide among our shareholders (excluding the Company itself to the extent that it is a shareholder by virtue of its holding any shares or
treasury shares) </FONT><FONT SIZE=2><I>in specie</I></FONT><FONT SIZE=2> or in kind the whole or any part of our assets (subject to any special rights attached to any shares issued by us in the
future) and may for that purpose set such value as he deems fair upon any one or more class or classes of property and may determine how that division shall be carried out as between the shareholders
or different classes of shareholders. The liquidator may, with that sanction, vest the whole or any part of the assets in trustees upon such trusts for the benefit of the shareholders as he with the
relevant authority determines, and the liquidation of the Company may be closed and the Company dissolved, but so that no shareholders shall be compelled to accept any shares or other property in
respect of which there is a liability. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Variation of Rights  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The rights or privileges attached to any class of shares may (unless otherwise provided by the terms of the issue of the shares of that class)
be varied or abrogated with the consent in writing of the holders of three-fourths in requisite amount of the issued shares of that class (excluding any shares of that class held as treasury shares)
or with the sanction of a special resolution passed at a separate general meeting of the shareholders of that class, but not otherwise. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transfer of Shares  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of our shares are in registered form and may be transferred by a transfer in any usual or common form or any form acceptable to the
directors and permitted by the Companies Act 2006 and any other relevant legislation. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
directors may decline to register a transfer of a share that is:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> not fully paid or on which we have a lien; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> (except where uncertificated shares are transferred without a written instrument) not lodged duly stamped (if it is required to be duly
stamped) at our registered office or at such other place as the directors may appoint; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> (except where a certificate has not been issued) not accompanied by the certificate of the share to which it relates or such other evidence
reasonably required by the directors to show the right of the transferor to make the transfer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in respect of more than one class of share; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the case of a transfer to joint holders of a share, the number of joint holders to whom the share is to be transferred exceeds four. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=14,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=320681,FOLIO='10',FILE='DISK133:[18ZBZ1.18ZBZ49801]DA49801A.;9',USER='NDEWIND',CD='10-JUL-2018;09:57' -->
<A NAME="page_da49801_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Capital Variations  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may, by ordinary resolution, consolidate and divide all or any of our share capital into shares of a larger nominal amount than our existing
shares or sub-divide our shares, or any of them, into shares of a smaller amount than our existing shares. Subject to the provisions of the Companies Act 2006 and any other relevant legislation, we
may by special resolution reduce our share capital, any capital redemption reserve fund or any share premium account and may redeem or purchase any of our own shares. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pre-emption Rights  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are no rights of pre-emption under our articles of association in respect of transfers of issued ordinary shares. In certain
circumstances, our shareholders may have statutory pre-emption rights under the Companies Act 2006 in respect of the allotment of new shares in the Company. These statutory pre-emption rights, when
applicable, would require us to offer new shares for allotment to existing shareholders on a pro rata basis before allotting them to other persons. In such circumstances, the procedure for the
exercise of such statutory pre-emption rights would be set out in the documentation by which such ordinary shares would be offered to our shareholders. These statutory pre-emption rights may be
disapplied by a special resolution passed by shareholders in a general meeting in accordance with the provisions of the Companies Act 2006. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Directors  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Number  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless and until we in a general meeting of our shareholders otherwise determine, the number of directors shall not be subject to any maximum
but shall not be less than two. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Borrowing Powers  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under our directors' general power to manage our business, our directors may exercise all the powers of the Company to borrow money and to
mortgage or charge our undertaking, property and uncalled capital or parts thereof and to issue debentures and other securities, whether outright or as collateral security for any debt, liability or
obligation of the Company or of any third party. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Directors' Interests and Restrictions  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;The
board may, in accordance with our articles of association and the requirements of the Companies Act 2006, authorize a matter proposed to us which would, if not
authorized, involve a breach by a director of his duty under section&nbsp;175 of the Companies Act 2006 to avoid a situation in which he has, or can have, a direct or indirect interest that
conflicts, or possibly may conflict, with our interests. A director is not required, by reason of being a director, to account to the Company for any remuneration or other benefit that he derives from
a relationship involving a conflict of interest or possible conflict of interest that has been authorized by the board. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Subject
to the provisions of any relevant legislation and provided that he has disclosed to the directors the nature and extent of any material interest of his, a
director may be a party to, or otherwise interested in, any transaction, contract or arrangement with us and he may be a director or other officer of, or employed by, or a party to any transaction or
arrangement with, or otherwise interested in any body corporate promoted by the Company or in which the Company is otherwise interested and that director shall not, by reason of his office, be
accountable to the Company for any benefit that he derives from any such office or employment or from any such transaction or arrangement or from any interest in any such body corporate; and no such </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=15,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=562936,FOLIO='11',FILE='DISK133:[18ZBZ1.18ZBZ49801]DA49801A.;9',USER='NDEWIND',CD='10-JUL-2018;09:57' -->
<A NAME="page_da49801_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>transaction
or arrangement shall be liable to be voided on the ground of any such interest or benefit. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;Except
as provided in our articles of association, a director shall not vote at a meeting of the directors in respect of any transaction or arrangement or any other
proposal whatsoever in which he has an interest (together with any person connected with him within the meaning of section&nbsp;252 of the Companies Act 2006), other than (i)&nbsp;an interest in
shares or debentures or other securities of the Company, (ii)&nbsp;where permitted by the terms of any authorization of a conflict of interest or by an ordinary resolution, (iii)&nbsp;where the
interest cannot reasonably be regarded as likely to give rise to a conflict of interest, or (iv)&nbsp;in the circumstances set out in paragraph&nbsp;(d) below, and shall not be counted in the
quorum at a meeting in relation to any resolution on which he is not entitled to vote. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;A
director shall (in the absence of some material interest other than those indicated below) be entitled to vote (and be counted in the quorum) in respect of any
resolution concerning any of the following matters: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;the
giving of any guarantee, security or indemnity in respect of an obligation incurred by him or for the benefit us or any of our subsidiaries; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;any
proposal concerning an offer of shares or debentures or other securities of or by us or any of our subsidiaries for subscription or purchase or exchange in which
offer he is or will be interested as a participant in the underwriting, sub-underwriting or guaranteeing of such offer; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;any
proposal concerning any other company in which he is interested, directly or indirectly and whether as an officer or shareholder or otherwise, provided that he
(together with persons connected with him) does not to his knowledge hold an interest in shares representing one percent or more of the issued shares of any class of such company (or of any third
company through which his interest is derived) or of the voting rights available to shareholders of the relevant company; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;&nbsp;any
proposal concerning arrangements pursuant to which benefits are made available to our employees and/or directors and which does not provide special benefits for
directors or former directors; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;&nbsp;any
proposal under which he may benefit concerning the giving of indemnities to our directors or other officers that the directors are empowered to give under our
articles of association; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;&nbsp;any
proposal under which he may benefit concerning the purchase or maintenance of insurance for any of our directors or other officers; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)&nbsp;&nbsp;any
proposal under which he may benefit concerning the provision to directors of funds to meet expenditures in defending proceedings. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;Where
proposals are under consideration to appoint two or more directors to offices or employments with us or with any company in which we are interested or to fix or
vary the terms of such appointments, such proposals may be divided and considered in relation to each director separately and in such case each of the directors concerned (if not debarred from voting
under paragraph&nbsp;(d)(iv) above) shall be entitled to vote (and be counted in the quorum) in respect of each resolution, except that concerning his own appointment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;If
any question shall arise at any meeting as to the materiality of a director's interest or as to the entitlement of any director to vote and such question is not
resolved by his agreeing voluntarily to abstain from voting, such question shall be referred to the chairman of the meeting </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=16,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=287513,FOLIO='12',FILE='DISK133:[18ZBZ1.18ZBZ49801]DA49801A.;9',USER='NDEWIND',CD='10-JUL-2018;09:57' -->
<A NAME="page_da49801_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>(or
where the interest concerns the chairman himself to the deputy chairman of the meeting) and his ruling in relation to any director shall be final and conclusive, except in a case where the nature
or extent of the interests of the director concerned have not been fairly disclosed. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Remuneration  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;Each
of the directors may (in addition to any amounts payable under paragraph&nbsp;(b) and (c)&nbsp;below or under any other provision of our articles of
association) be paid out of the funds of the Company such sum by way of directors' fees as the directors may from time to time determine. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Any
director who is appointed to hold any employment or executive office with us or who, by our request, goes or resides abroad for any purposes of the Company or who
otherwise performs services that in the opinion of the directors are outside the scope of his ordinary duties may be paid such additional remuneration (whether by way of salary, commission,
participation in profits or otherwise) as the directors (or any duly authorized committee of the directors) may determine and either in addition to or in lieu of any remuneration provided for by or
pursuant to any other Article. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;Each
director may be paid his reasonable traveling expenses (including hotel and incidental expenses) of attending and returning from meetings of the directors or
committees of the directors or general meetings or any separate meeting of the holders of any class of our shares or any other meeting that as a director he is entitled to attend and shall be paid all
expenses properly and reasonably incurred by him in the conduct of the Company's business or in the discharge of his duties as a director. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pensions and Other Benefits  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The directors may exercise all the powers of the Company to provide benefits, either by the payment of gratuities or pensions or by insurance or
in any other manner whether similar to the foregoing or not, for any director or former director, or any person who is or was at any time employed by, or held an executive or other office or place of
profit in, the Company or any body corporate that is or has been a subsidiary of the Company or a predecessor of the business of the Company or of any such subsidiary and for the families and persons
who are or was a dependent of any such persons and for the purpose of providing any such benefits contribute to any scheme trust or fund or pay any premiums. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Appointment and Retirement of Directors  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;The
directors shall have power to appoint any person who is permitted by the Companies Act 2006 and any other relevant legislation and is willing to act to be a
director, either to fill a casual vacancy or as an additional director but so that the total number of directors shall not exceed the maximum number fixed (if any) by or in accordance with our
articles of association. Any director so appointed shall retire from office at our annual general meeting following such appointment. Any director so retiring shall be eligible for re-election. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Subject
as provided in our articles of association, the shareholders may by ordinary resolution elect any person who is willing to act as a director either to fill a
casual vacancy or as an addition to the existing directors or to replace a director removed from office under our articles of association but so that the total number of directors shall not at any one
time exceed any maximum number fixed by or in accordance with our articles of association. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;At
each annual general meeting a minimum number equal to one-third of the number of those directors who are not due to retire at the annual general meeting under
sub-paragraph&nbsp;(a) above (referred to for as the purposes of this paragraph relevant directors) (or, if their number is </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=17,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=615154,FOLIO='13',FILE='DISK133:[18ZBZ1.18ZBZ49801]DA49801A.;9',USER='NDEWIND',CD='10-JUL-2018;09:57' -->
<A NAME="page_da49801_1_14"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>not
a multiple of three, the number nearest to but not greater than one-third) shall retire from office. Directors retiring under paragraph&nbsp;(e) below shall be counted as part of this minimum
number. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;The
directors to retire by rotation pursuant to paragraph&nbsp;(c) above shall include (so far as necessary to obtain the minimum number required and after taking into
account the directors to retire under paragraph&nbsp;(e) below) any relevant director who wishes to retire and not to offer himself for re-election. Any further directors to retire shall be those of
the other relevant directors who have been longest in office since their last re-election or appointment and so that as between persons who became or were last re-elected directors on the same day,
those to retire shall (unless they otherwise agree among themselves) be determined by lot. A retiring director shall be eligible for re-election. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;In
any event, each director shall retire and shall (unless his terms of appointment with the Company specify otherwise) be eligible for re-election at the annual general
meeting held in the third calendar year (or such earlier calendar year as may be specified for this purpose in his terms of appointment with the Company) following his last appointment, election or
re-election at any general meeting of the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;At
the meeting at which a director retires under any provision of our articles of association, the shareholders may by ordinary resolution fill the vacated office by
appointing a person eligible for election as a director under our articles of association to it, and in default the retiring director shall be deemed to have been re-appointed except where: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;that
director has given notice to us that he is unwilling to be elected; or </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;at
such meeting it is expressly resolved not to fill such vacated office or a resolution for the reappointment of such director shall have been put to the meeting and
not passed. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;In
the event of the vacancy not being filled at such meeting, it may be filled by the directors as a casual vacancy in accordance with sub-paragraph&nbsp;(a) above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;The
retirement of a director pursuant to paragraphs&nbsp;(c), (d)&nbsp;and (e)&nbsp;shall not have effect until the conclusion of the relevant meeting except where
a resolution is passed to elect some other person in the place of the retiring director or a resolution for his re-election is put to the meeting and not passed and accordingly a retiring director who
is re-elected or deemed to have been re-elected will continue in office without break. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Company Name  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The directors may resolve to change the Company's name. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Indemnity of Officers  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the provisions of any relevant legislation, each of our directors and other officers (excluding an auditor) are entitled to be
indemnified by us against all liabilities incurred by him in the execution and discharge of his duties or in relation to those duties. The Companies Act 2006 renders void an indemnity for a director
against any liability attaching to him in connection with any negligence, default, breach of duty or breach of trust in relation to the company of which he is a directors as described in
"&#151;Differences in Corporate Law&#151;Liability of Directors and Officers." </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Shareholders Meetings  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual General Meetings  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We shall in each year hold a general meeting of our shareholders in addition to any other meetings in that year, and shall specify the meeting
as such in the notice convening it. The annual general meeting shall be held at such time and place as the directors may appoint. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=18,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=230568,FOLIO='14',FILE='DISK133:[18ZBZ1.18ZBZ49801]DA49801A.;9',USER='NDEWIND',CD='10-JUL-2018;09:57' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc49801_1_15"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A> </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Calling of General Meetings  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The directors may call a general meeting of shareholders. The directors must call a general meeting if the shareholders and the Companies Act
2006 require them to do so. The arrangements for the calling of general meetings are described in "&#151;Differences in Corporate Law&#151;Notice of General Meetings." </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Quorum of Meetings  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No business shall be transacted at any general meeting unless a quorum is present when the meeting proceeds to business but the absence of a
quorum shall not preclude the appointment of a chairman that shall not be treated as part of the business of a meeting. One or more qualifying persons present at a meeting and between them holding (or
being the proxy or corporate representative of the holders of) at least one-third in number of the issued shares (excluding any shares held as treasury shares) entitled to vote on the business to be
transacted are a quorum. A qualifying person for these purposes is an individual who is a member, a person authorized to act as the representative of a member (being a corporation) in relation to the
meeting or a person appointed as proxy of a member in relation to the meeting. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other U.K. Law Considerations  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Mandatory Purchases and Acquisitions  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to sections&nbsp;979 to 991 of the Companies Act 2006, where a takeover offer has been made for the Company and the offeror has
acquired or unconditionally contracted to acquire not less than 90&nbsp;percent of the voting rights carried by those shares, the offeror may give notice, to the holder of any shares to which the
offer relates which the offeror has not acquired or unconditionally contracted to acquire that he wishes to acquire and is entitled to so acquire, to acquire those shares of the same terms as the
general offer. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Disclosure of Interest in Shares  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to Part&nbsp;22 of the Companies Act 2006 and our articles of association, we are empowered by notice in writing to require any
person whom we know to be, or have reasonable
cause to believe to be, interested in the Company, our shares or, at any time during the three years immediately preceding the date on which the notice is issued has been so interested, within a
reasonable time to disclose to us particulars of any interest, rights, agreements or arrangements affecting any of the shares held by that person or in which such other person as aforesaid is
interested (so far as is within his knowledge). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
our articles of association, if a person defaults in supplying us with the required particulars in relation to the shares in question ("default shares"), the directors may be
notice direct that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in respect of the default shares, the relevant member shall not be entitled to vote or exercise any other right conferred by membership in
relation to general meetings; and/or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> where the default shares represent at least 0.25&nbsp;percent of their class, (a)&nbsp;any dividend or other money payable in respect of
the default shares shall be retained by us without liability to pay interest, and/or (b)&nbsp;no transfers by the relevant member of shares other than certain approved transfers may be registered
(unless the member himself is not in default and the transfer does not relate to default shares), and/or (c)&nbsp;any shares held by the relevant number in uncertificated form shall be converted
into certificated form. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=19,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=880101,FOLIO='15',FILE='DISK133:[18ZBZ1.18ZBZ49801]DC49801A.;33',USER='JTAYLORA',CD='10-JUL-2018;10:18' -->
<A NAME="page_dc49801_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Purchase of Own Shares  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under English law, a public limited company may only purchase its own shares out of the distributable profits of the company or the proceeds of
a fresh issue of shares made for the purpose of financing the purchase. A limited company may not purchase its own shares if as a result of the purchase there would no longer be any issued shares of
the company other than redeemable shares or shares held as treasury shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the above, we may purchase our own shares in the manner prescribed below. We may purchase on a recognized investment exchange our own fully paid shares pursuant to an ordinary
resolution of the Company. The resolution authorizing the purchase must:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> specify the maximum number of shares authorized to be acquired; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> determine the maximum and minimum prices that may be paid for the shares; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> specify a date, not being later than five years after the passing of the resolution, on which the authority to purchase is to expire. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may purchase our own fully paid shares otherwise than on a recognized investment exchange pursuant to a purchase contract authorized by special resolution of the Company before the
purchase takes place. Any authority will not be effective if any shareholder from whom we propose to purchase shares votes on the resolution and the resolution would not have been passed if he had not
done so. The resolution authorizing the purchase must specify a date, not being later than five years after the passing of the resolution, on which the authority to purchase is to expire. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Registration Rights  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Investors' Rights Agreement, dated February&nbsp;23, 2015, or the Investors' Rights Agreement, certain of our shareholders have
registration rights for the resale of the ordinary shares held by them. Under this agreement, the holders of approximately 84,948,400 ordinary shares (including in the form of ADSs) have the right to
require us to register the offer and sale of their ordinary shares, or the registrable securities (including in the form of ADSs), or to include such registrable securities in registration statements
we file, in each case as described below. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Demand Registration Rights  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At any time after six months following our IPO, the holders of more than fifty percent of the registrable securities than outstanding have the
right to demand that we use our best efforts to file&nbsp;a registration statement, provided that the anticipated aggregated offering price for such offering must exceed $10&nbsp;million. We are
only obligated to file up to two registration statements in connection with the exercise of demand registration rights. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, at any time after we qualify to file&nbsp;a registration statement on Form&nbsp;F-3 (or any substantially similar form such as Form&nbsp;S-3), any holder of
registrable securities has the right to demand that we use our commercially reasonable efforts to file&nbsp;a registration statement on Form&nbsp;F-3 (or any substantially similar form such as
Form&nbsp;S-3) covering at least $5&nbsp;million of registrable securities. We are not obligated to file more than two such registration statements in any 12-month period. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Right to Participate in Company Registrations  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we propose to register (other than in certain excluded registrations) any ordinary shares or ADSs representing such ordinary shares,
shareholders who have entered into the Investors' Rights Agreement are entitled to notice of such registration and to include their registrable securities in that registration. The registration of
such shareholders' registrable securities pursuant to a company </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=20,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=789362,FOLIO='16',FILE='DISK133:[18ZBZ1.18ZBZ49801]DC49801A.;33',USER='JTAYLORA',CD='10-JUL-2018;10:18' -->
<A NAME="page_dc49801_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>registration
does not relieve us of the obligation to effect a demand registration. The managing underwriter has the right to limit the number of registrable securities included in a company
registration if the managing underwriter believes it would interfere with the successful marketing of the ordinary shares or ADSs. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expenses of Registration  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to limited exceptions, the Investors' Rights Agreement provides that we must pay all registration expenses in connection with the
registration rights set forth above. The Investors' Rights Agreement contains customary indemnification and contribution provisions. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Termination  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registration rights set forth above terminate upon the earlier of (1)&nbsp;sale of the company (2)&nbsp;as to a particular holder, when
such holder can sell all of its ordinary shares (including in the form of ADSs) without limitation during a three-month period without registration pursuant to Rule&nbsp;144 under the Securities Act
or another exemption; or (3)&nbsp;the fifth anniversary of the completion of our IPO. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Differences in Corporate Law  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The applicable provisions of the Companies Act 2006 differ from laws applicable to U.S. corporations and their
shareholders. Set forth below is a summary of certain differences between the provisions of the Companies Act 2006 applicable to us and the Delaware General Corporation Law relating to shareholders'
rights and protections. This summary is not intended to be a complete discussion of the respective rights and it is qualified in its entirety by reference to Delaware law and English
law</I></FONT><FONT SIZE=2>. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="157pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="34%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="34%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>England and Wales </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Delaware </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of Directors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Under the Companies Act 2006, a public limited company must have at least two directors and the number of directors may be fixed by or in the manner provided in a company's articles of association.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the bylaws.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Removal of Directors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under the Companies Act 2006, shareholders may remove a director without cause by an ordinary resolution (which is passed by a simple
majority of those voting in person or by proxy at a general meeting) irrespective of any provisions of any service contract the director has with the company, provided that 28 clear days' notice of the resolution is given to the company and its
shareholders and certain other procedural requirements under the Companies Act 2006 are followed (such as allowing the director to make representations against his or her removal either at the meeting or in writing).</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under Delaware law, unless otherwise provided in the certificate of incorporation, directors may be removed from office, with or without
cause, by a majority stockholder vote, though in the case of a corporation whose board is classified, stockholders may effect such removal only for cause.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=21,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=337178,FOLIO='17',FILE='DISK133:[18ZBZ1.18ZBZ49801]DC49801A.;33',USER='JTAYLORA',CD='10-JUL-2018;10:18' -->
<A NAME="page_dc49801_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="157pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="34%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="34%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>England and Wales </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Delaware </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vacancies on the Board of Directors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under English law, the procedure by which directors (other than a company's initial directors) are appointed is generally set out in a
company's articles of association, provided that where two or more persons are appointed as directors of a public limited company by resolution of the shareholders, resolutions appointing each director must be voted on individually.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under Delaware law, vacancies on a corporation's board of directors, including those caused by an increase in the number of directors, may be filled by a
majority of the remaining directors.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Annual General Meeting</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under the Companies Act 2006, a public limited company must hold an annual general meeting in each six-month period following the company's
annual accounting reference date.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be designated from
time to time by the board of directors or as provided in the certificate of incorporation or by the bylaws.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General Meeting</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under the Companies Act 2006, a general meeting of the shareholders of a public limited company may be called by the directors.<BR></FONT>
<FONT SIZE=2><BR>
Shareholders holding at least 5% of the paid-up capital of the company carrying voting rights at general meetings can require the directors to call a general meeting.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be
authorized by the certificate of incorporation or by the bylaws.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=22,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=1007604,FOLIO='18',FILE='DISK133:[18ZBZ1.18ZBZ49801]DC49801A.;33',USER='JTAYLORA',CD='10-JUL-2018;10:18' -->
<A NAME="page_dc49801_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="157pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="34%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="34%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>England and Wales </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Delaware </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notice of General Meetings</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under the Companies Act 2006, 21 clear days' notice must be given for an annual general meeting and any resolutions to be proposed at the
meeting. Subject to a company's articles of association providing for a longer period, at least 14 clear days' notice is required for any other general meeting. In addition, certain matters (such as the removal of directors or auditors) require
special notice, which is 28 clear days' notice. The shareholders of a company may in all cases consent to a shorter notice period, the proportion of shareholders' consent required being 100% of those entitled to attend and vote in the case of an
annual general meeting and, in the case of any other general meeting, a majority in number of the members having a right to attend and vote at the meeting, being a majority who together hold not less than 95% in nominal value of the shares giving a
right to attend and vote at the meeting.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given
to each stockholder entitled to vote at the meeting not less than 10 nor more than 60&nbsp;days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the meeting.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proxy</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under the Companies Act 2006, at any meeting of shareholders, a shareholder may designate another person to attend, speak and vote at the
meeting on their behalf by proxy.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no
such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=23,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=111332,FOLIO='19',FILE='DISK133:[18ZBZ1.18ZBZ49801]DC49801A.;33',USER='JTAYLORA',CD='10-JUL-2018;10:18' -->
<A NAME="page_dc49801_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="157pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="34%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="34%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>England and Wales </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Delaware </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Preemptive Rights</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under the Companies Act 2006, "equity securities" (being (i)&nbsp;shares in the company other than shares that, with respect to dividends and capital, carry
a right to participate only up to a specified amount in a distribution ("ordinary shares") or (ii)&nbsp;rights to subscribe for, or to convert securities into, ordinary shares) proposed to be allotted for cash must be offered first to the existing
equity shareholders in the company in proportion to the respective nominal value of their holdings, unless an exception applies or a special resolution to the contrary has been passed by shareholders in a general meeting or the articles of
association provide otherwise in each case in accordance with the provisions of the Companies Act 2006.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under Delaware law, unless otherwise provided in a corporation's certificate of incorporation, a stockholder does not, by operation of law, possess
preemptive rights to subscribe to additional issuances of the corporation's stock.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=24,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=967119,FOLIO='20',FILE='DISK133:[18ZBZ1.18ZBZ49801]DC49801A.;33',USER='JTAYLORA',CD='10-JUL-2018;10:18' -->
<A NAME="page_dc49801_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="157pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="34%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="34%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>England and Wales </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Delaware </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Liability of Directors and Officers</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under the Companies Act 2006, any provision (whether contained in a company's articles of association or any contract or otherwise) that
purports to exempt a director of a company (to any extent) from any liability that would otherwise attach to him in connection with any negligence, default, breach of duty or breach of trust in relation to the company is void.<BR>
</FONT><FONT SIZE=2><BR>
Any provision by which a company directly or indirectly provides an indemnity (to any extent) for a director of the company or of an associated company against any liability attaching to him in connection with any negligence, default, breach of duty
or breach of trust in relation to the company of which he is a director is also void except as permitted by the Companies Act 2006, which provides exceptions for the company to (a)&nbsp;purchase and maintain insurance against such liability;
(b)&nbsp;provide a "qualifying third party indemnity" (being an indemnity against liability incurred by the director to a person other than the company or an associated company as long as he is successful in defending the claim or criminal
proceedings); and (c)&nbsp;provide a "qualifying pension scheme indemnity" (being an indemnity against liability incurred in connection with the company's activities as trustee of an occupational pension plan).</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Under Delaware law, a corporation's certificate of incorporation may include a provision eliminating or limiting the personal liability of a director to the corporation and its stockholders for damages arising from a breach of fiduciary duty as a
 director. However, no provision can limit the liability of a director for:<BR></FONT>
<BR>
<FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>any breach of the director's duty
of loyalty to the corporation or its stockholders;<BR></FONT>
<BR>
<FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>acts or omissions not in good
faith or that involve intentional misconduct or a knowing violation of law;<BR></FONT>
<BR>
<FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2> intentional or negligent payment
of unlawful dividends or stock purchases or redemptions; or<BR></FONT>
<BR>
<FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>any transaction from which the
director derives an improper personal benefit.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=25,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=192238,FOLIO='21',FILE='DISK133:[18ZBZ1.18ZBZ49801]DC49801A.;33',USER='JTAYLORA',CD='10-JUL-2018;10:18' -->
<A NAME="page_dc49801_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="157pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="34%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="34%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>England and Wales </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Delaware </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Voting Rights</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under English law, unless a poll is demanded by the shareholders of a company or is required by the chairman of the meeting or the company's articles of
association, shareholders shall vote on all resolutions on a show of hands. Under the Companies Act 2006, a poll may be demanded by (a)&nbsp;not fewer than five shareholders having the right to vote on the resolution; (b)&nbsp;any shareholder(s)
representing at least 10% of the total voting rights of all the shareholders having the right to vote on the resolution; or (c)&nbsp;any shareholder(s) holding shares in the company conferring a right to vote on the resolution being shares on which
an aggregate sum has been paid up equal to not less than 10% of the total sum paid up on all the shares conferring that right. A company's articles of association may provide more extensive rights for shareholders to call a poll.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of
capital stock held by such stockholder.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under English law, an ordinary resolution is passed on a show of hands if it is approved by a simple majority (more than 50%) of the votes
cast by shareholders present (in person or by proxy) and entitled to vote. If a poll is demanded, an ordinary resolution is passed if it is approved by holders representing a simple majority of the total voting rights of shareholders present (in
person or by proxy) who (being entitled to vote) vote on the resolution. Special resolutions require the affirmative vote of not less than 75% of the votes cast by shareholders present (in person or by proxy) at the meeting.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=26,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=842158,FOLIO='22',FILE='DISK133:[18ZBZ1.18ZBZ49801]DC49801A.;33',USER='JTAYLORA',CD='10-JUL-2018;10:18' -->
<A NAME="page_dc49801_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="157pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="34%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="34%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>England and Wales </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Delaware </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shareholder Vote on Certain Transactions</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 The Companies Act 2006 provides for schemes of arrangement, which are arrangements or compromises between a company and any class of shareholders or creditors and used in certain types of reconstructions, amalgamations, capital reorganizations or
 takeovers. These arrangements require:<BR></FONT>
<BR>
<FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>the approval at a shareholders' or
creditors' meeting convened by order of the court, of a majority in number of shareholders or creditors representing 75% in value of the capital held by, or debt owed to, the class of shareholders or creditors, or class thereof present and voting,
either in person or by proxy; and<BR></FONT>
<BR>
<FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>the approval of the
court.<BR></FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Generally, under Delaware law, unless the certificate of incorporation provides for the vote of a larger portion of the stock, completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation's assets or
 dissolution requires:<BR></FONT>
<BR>
<FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>the approval of the board of
directors; and<BR></FONT>
<BR>
<FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>approval by the vote of the
holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=27,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=720329,FOLIO='23',FILE='DISK133:[18ZBZ1.18ZBZ49801]DC49801A.;33',USER='JTAYLORA',CD='10-JUL-2018;10:18' -->
<A NAME="page_dc49801_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="157pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="34%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="34%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>England and Wales </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Delaware </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Standard of Conduct for Directors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Under English law, a director owes various statutory and fiduciary duties to the company, including:<BR></FONT>
<BR>
<FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>to act in the way he considers, in
good faith, would be most likely to promote the success of the company for the benefit of its members as a whole;<BR>
</FONT><BR>
<FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>to avoid a situation in which he
has, or can have, a direct or indirect interest that conflicts, or possibly conflicts, with the interests of the company;<BR></FONT>
<BR>
<FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>to act in accordance with the
company's constitution and only exercise his powers for the purposes for which they are conferred;<BR></FONT>
<BR>
<FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>to exercise independent
judgment;<BR></FONT>
<BR>
<FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>to exercise reasonable care, skill
and diligence;<BR></FONT>
<BR>
<FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>not to accept benefits from a
third party conferred by reason of his being a director or doing (or not doing) anything as a director; and<BR></FONT>
<BR>
<FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>a duty to declare any interest
that he has, whether directly or indirectly, in a proposed or existing transaction or arrangement with the company.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is
generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self-interest, on a well-informed basis and in a manner they reasonably believe to be in the best interest of the stockholders.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=28,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=988613,FOLIO='24',FILE='DISK133:[18ZBZ1.18ZBZ49801]DC49801A.;33',USER='JTAYLORA',CD='10-JUL-2018;10:18' -->
<A NAME="page_dc49801_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="157pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="34%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="34%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>England and Wales </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Delaware </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholder Suits</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Under English law, generally, the company, rather than its shareholders, is the proper claimant in an action in respect of a wrong done to the company or
where there is an irregularity in the company's internal management. Notwithstanding this general position, the Companies Act 2006 provides that (i)&nbsp;a court may allow a shareholder to bring a derivative claim (that is, an action in respect of
and on behalf of the company) in respect of a cause of action arising from a director's negligence, default, breach of duty or breach of trust and (ii)&nbsp;a shareholder may bring a claim for a court order where the company's affairs have been or
are being conducted in a manner that is unfairly prejudicial to some of its shareholders.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce the right itself. The complaint must:<BR></FONT>
<BR>
<FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>state that the plaintiff was a
stockholder at the time of the transaction of which the plaintiff complains or that the plaintiffs shares thereafter devolved on the plaintiff by operation of law; and<BR></FONT>
<BR>
<FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>allege with particularity the
efforts made by the plaintiff to obtain the action the plaintiff desires from the directors and the reasons for the plaintiff's failure to obtain the action; or<BR>
</FONT><BR>
<FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>state the reasons for not making
the effort.<BR></FONT> <FONT SIZE=2><BR>
Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit. The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


City Code on Takeovers and Mergers  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If at the time of a takeover offer the U.K. Panel on Takeovers and Mergers (the "Takeover Panel") determines that we have our place of central
management and control in the United Kingdom, we would be subject to the U.K. City Code on Takeovers and Mergers (the "Takeover Code"), which is issued and administered by the Takeover Panel. The
Takeover Code provides a framework within which takeovers of companies subject to it are conducted, including, in particular, certain rules in respect of mandatory offers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
July 2018, the Takeover Panel confirmed that, based on our current circumstances, we are not subject to the Takeover Code. As a result, our shareholders are not entitled to the
benefit of certain takeover offer protections provided under the Takeover Code. We believe that this position is unlikely to change at any time in the near future but, in accordance with good
practice, we will review the situation on a regular basis and consult with the Takeover Panel if there is any change in our circumstances which may have a bearing on whether the Takeover Panel would
determine our place of central management and control to be in the United Kingdom. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Exchange Controls  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are no governmental laws, decrees, regulations or other legislation in the United Kingdom that may affect the import or export of capital,
including the availability of cash and cash equivalents for use by us, or that may affect the remittance of dividends, interest, or other payments by us to non-resident holders of our ordinary shares
or ordinary shares, other than withholding tax requirements. There is no limitation imposed by English law or our articles of association on the right of non-residents to hold or vote shares. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=29,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=306239,FOLIO='25',FILE='DISK133:[18ZBZ1.18ZBZ49801]DC49801A.;33',USER='JTAYLORA',CD='10-JUL-2018;10:18' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de49801_1_26"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de49801_description_of_american_depositary_shares"> </A>
<A NAME="toc_de49801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF AMERICAN DEPOSITARY SHARES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Citibank, N.A. has agreed to act as the depositary bank for the American Depositary Shares. Citibank's depositary offices are located at 388
Greenwich Street, New York, New York 10013. American Depositary Shares are frequently referred to as "ADSs" and represent ownership interests in securities that are on deposit with the depositary
bank. ADSs may be represented by certificates that are commonly known as "American Depositary Receipts" or "ADRs." The depositary bank typically appoints a custodian to safekeep the securities on
deposit. In this case, the custodian is Citibank, N.A. London Branch, having its principal office at Citigroup Centre, Canada Square, Canary Wharf, London&nbsp;E14&nbsp;5LB, England. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have appointed Citibank as depositary bank pursuant to a deposit agreement. A copy of the deposit agreement is on file with the SEC under cover of a Registration Statement on
Form&nbsp;F-6. You may obtain a copy of the deposit agreement from the SEC's Public Reference Room at 100&nbsp;F Street, N.E.,
Washington, D.C. 20549 and from the SEC's website (www.sec.gov). Please refer to Registration Number&nbsp;333-203642 when retrieving such copy. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are providing you with a summary description of the material terms of the ADSs and of your material rights as an owner of ADSs. Please remember that summaries by their nature lack the
precision of the information summarized and that the rights and obligations of an owner of ADSs will be determined by reference to the terms of the deposit agreement and not by this summary. We urge
you to review the deposit agreement in its entirety. The portions of this summary description that are italicized describe matters that may be relevant to the ownership of ADSs but that may not be
contained in the deposit agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
ADS represents the right to receive and to exercise the beneficial ownership interests in 6&nbsp;ordinary shares that are on deposit with the depositary bank and/or custodian. An
ADS also represents the right to receive, and to exercise the beneficial interests in any other property received by the depositary bank or the custodian on behalf of the owner of the ADS but that has
not been distributed to the owners of ADSs because of legal restrictions or practical considerations. The custodian, the depositary bank and their respective nominees will hold all deposited property
for the benefit of the holders and beneficial owners of ADSs. The deposited property does not constitute the proprietary assets of the depositary bank, the custodian or their nominees. Beneficial
ownership in the deposited property will under the terms of the deposit agreement be vested in the beneficial owners of the ADSs. The depositary bank, the custodian and their respective nominees will
be the record holders of the deposited property represented by the ADSs for the benefit of the holders and beneficial owners of the corresponding ADSs. A beneficial owner of ADSs may or may not be the
holder of ADSs. Beneficial owners of ADSs will be able to receive, and to exercise beneficial ownership interests in the deposited property only through the registered holders of the ADSs, the
registered holders of the ADSs (on behalf of the applicable ADS owners) only through the depositary bank, and the depositary bank (on behalf of the owners of the corresponding ADSs) directly, or
indirectly through the custodian or their respective nominees, in each case upon the terms of the deposit agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you become an owner of ADSs, you will become a party to the deposit agreement and therefore will be bound to its terms and to the terms of any ADR that represents your ADSs. The
deposit agreement and the ADR specify our rights and obligations as well as your rights and obligations as an owner of ADSs and those of the depositary bank. As an ADS holder you appoint the
depositary bank to act on your behalf in certain circumstances. The deposit agreement and the ADRs are governed by New York law. However, our obligations to the holders of ordinary shares will
continue to be governed by the laws of England and Wales, which may be different from the laws in the United States. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, applicable laws and regulations may require you to satisfy reporting requirements and obtain regulatory approvals in certain circumstances. You are solely responsible for
complying with such reporting requirements and obtaining such approvals. Neither the depositary bank, the custodian, us or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=30,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=319459,FOLIO='26',FILE='DISK133:[18ZBZ1.18ZBZ49801]DE49801A.;9',USER='JTAYLORA',CD='10-JUL-2018;10:35' -->
<A NAME="page_de49801_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>any
of their or our respective agents or affiliates shall be required to take any actions whatsoever on your behalf to satisfy such reporting requirements or obtain such regulatory approvals under
applicable laws and regulations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>As an owner of ADSs, we will not treat you as one of our shareholders and you will not have direct shareholder rights. The depositary bank will hold on your
behalf the shareholder rights attached to the ordinary shares underlying your ADSs. As an owner of ADSs you will be able to exercise the shareholders rights for the ordinary shares represented by your
ADSs through the depositary bank only to the extent contemplated in the deposit agreement. To exercise any shareholder rights not contemplated in the deposit agreement you will, as an ADS owner, need
to arrange for the cancellation of your ADSs and become a direct shareholder.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
an owner of ADSs, you may hold your ADSs either by means of an ADR registered in your name, through a brokerage or safekeeping account, or through an account established by the
depositary bank in your name reflecting the registration of uncertificated ADSs directly on the books of the depositary bank (commonly referred to as the "direct registration system" or "DRS"). The
direct registration system reflects the uncertificated (book-entry) registration of ownership of ADSs by the depositary bank. Under the direct registration system, ownership of ADSs is evidenced by
periodic statements issued by the depositary bank to the holders of the ADSs. The direct registration system includes automated transfers between the depositary bank and The Depository Trust Company
("DTC"), the central book-entry clearing and settlement system for equity securities in the United States. If you decide to hold your ADSs through your brokerage or safekeeping account, you must rely
on the procedures of your broker or bank to assert your rights as ADS owner. Banks and brokers typically hold securities such as the ADSs through clearing and settlement systems such as DTC. The
procedures of such clearing and settlement systems may limit your ability to exercise your rights as an owner of ADSs. Please consult with your broker or bank if you have any questions concerning
these limitations and procedures. All ADSs held through DTC will be registered in the name of a nominee of DTC. This summary description assumes you have opted to own the ADSs directly by means of an
ADS registered in your name and, as such, we will refer to you as the "holder." When we refer to "you," we assume the reader owns ADSs and will own ADSs at the relevant time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registration of the ordinary shares in the name of the depositary bank or the custodian shall, to the maximum extent permitted by applicable law, vest in the depositary bank or the
custodian the record ownership in the applicable ordinary shares with the beneficial ownership rights and interests in such ordinary shares being at all times vested with the beneficial owners of the
ADSs representing the ordinary shares. The depositary bank or the custodian shall at all times be entitled to exercise the beneficial ownership rights in all deposited property, in each case only on
behalf of the holders and beneficial owners of the ADSs representing the deposited property. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends and Distributions  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a holder of ADSs, you generally have the right to receive the distributions we make on the securities deposited with the custodian. Your
receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms of the deposit agreement in
proportion to the number of ADSs held as of the specified record date, after deduction of the applicable fees, taxes and expenses. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Distributions of Cash  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whenever we make a cash distribution for the securities on deposit with the custodian, we will deposit the funds with the custodian. Upon
receipt of confirmation of the deposit of the requisite funds, the depositary bank will arrange for the funds to be converted into U.S. dollars and for the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=31,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=617792,FOLIO='27',FILE='DISK133:[18ZBZ1.18ZBZ49801]DE49801A.;9',USER='JTAYLORA',CD='10-JUL-2018;10:35' -->
<A NAME="page_de49801_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>distribution
of the U.S. dollars to the holders, subject to the laws and regulations of England and Wales. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
conversion into U.S. dollars will take place only if practicable and if the U.S. dollars are transferable to the United States. The depositary bank will apply the same method for
distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in respect of securities on deposit. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
distribution of cash will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. The depositary bank will hold
any cash amounts it is unable to distribute in a non-interest bearing account for the benefit of the applicable holders and beneficial owners of ADSs until the distribution can be effected or the
funds that the depositary bank holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Distributions of Shares  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whenever we make a free distribution of ordinary shares for the securities on deposit with the custodian, we will deposit the applicable number
of ordinary shares with the custodian. Upon receipt of confirmation of such deposit, the depositary bank will </FONT><FONT SIZE=2><I>either</I></FONT><FONT SIZE=2> distribute to holders new ADSs
representing the ordinary shares deposited </FONT><FONT SIZE=2><I>or</I></FONT><FONT SIZE=2> modify the ADS-to-ordinary share ratio, in which case each ADS you hold will represent rights and
interests in the additional ordinary shares so deposited. Only whole new ADSs will be distributed. Fractional entitlements will be sold and the proceeds of such sale will be distributed as in the case
of a cash distribution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
distribution of new ADSs or the modification of the ADS-to-ordinary share ratio upon a distribution of ordinary shares will be made net of the fees, expenses, taxes and governmental
charges payable by holders under the terms of the deposit agreement. In order to pay such taxes or governmental charges, the depositary bank may sell all or a portion of the new ordinary shares so
distributed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
such distribution of new ADSs will be made if it would violate a law (i.e.,&nbsp;the U.S. securities laws) or if it is not operationally practicable. If the depositary bank does not
distribute new ADSs as described above, it may sell the ordinary shares received upon the terms described in the deposit agreement and will distribute the proceeds of the sale as in the case of a
distribution of cash. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Distributions of Rights  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whenever we intend to distribute rights to purchase additional ordinary shares, we will give prior notice to the depositary bank and we will
assist the depositary bank in determining whether it is lawful and reasonably practicable to distribute rights to purchase additional ADSs to holders. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
depositary bank will establish procedures to distribute rights to purchase additional ADSs to holders and to enable such holders to exercise such rights if it is lawful and
reasonably practicable to make the rights available to holders of ADSs, and if we provide all of the documentation contemplated in the deposit agreement (such as opinions to address the lawfulness of
the transaction). You may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of your rights. The depositary bank is not obligated to
establish procedures to facilitate the
distribution and exercise by holders of rights to purchase new ordinary shares other than in the form of ADSs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
depositary bank will </FONT><FONT SIZE=2><I>not</I></FONT><FONT SIZE=2> distribute the rights to you if:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We do not timely request that the rights be distributed to you or we request that the rights not be distributed to you; or </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=32,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=397805,FOLIO='28',FILE='DISK133:[18ZBZ1.18ZBZ49801]DE49801A.;9',USER='JTAYLORA',CD='10-JUL-2018;10:35' -->
<A NAME="page_de49801_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We fail to deliver satisfactory documents to the depositary bank; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> It is not reasonably practicable to distribute the rights. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
depositary bank will sell the rights that are not exercised or not distributed if such sale is lawful and reasonably practicable. The proceeds of such sale will be distributed to
holders as in the case of a cash distribution. If the depositary bank is unable to sell the rights, it will allow the rights to lapse. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Elective Distributions  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whenever we intend to distribute a dividend payable at the election of shareholders either in cash or in additional shares, we will give prior
notice thereof to the depositary bank and will indicate whether we wish the elective distribution to be made available to you. In such
case, we will assist the depositary bank in determining whether such distribution is lawful and reasonably practicable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
depositary bank will make the election available to you only if it is reasonably practicable and if we have provided all of the documentation contemplated in the deposit agreement.
In such case, the depositary bank will establish procedures to enable you to elect to receive either cash or additional ADSs, in each case as described in the deposit agreement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the election is not made available to you, you will receive either cash or additional ADSs, depending on what a shareholder in England and Wales would receive upon failing to make an
election, as more fully described in the deposit agreement. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Distributions  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whenever we intend to distribute property other than cash, ordinary shares or rights to purchase additional ordinary shares, we will notify the
depositary bank in advance and will indicate whether we wish such distribution to be made to you. If so, we will assist the depositary bank in determining whether such distribution to holders is
lawful and reasonably practicable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
it is reasonably practicable to distribute such property to you and if we provide all of the documentation contemplated in the deposit agreement, the depositary bank will distribute
the property to the holders in a manner it deems practicable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
distribution will be made net of fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes and
governmental charges, the depositary bank may sell all or a portion of the property received. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
depositary bank will </FONT><FONT SIZE=2><I>not</I></FONT><FONT SIZE=2> distribute the property to you and will sell the property if:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We do not request that the property be distributed to you or if we ask that the property not be distributed to you; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We do not deliver satisfactory documents to the depositary bank; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The depositary bank determines that all or a portion of the distribution to you is not reasonably practicable. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
proceeds of such a sale will be distributed to holders as in the case of a cash distribution. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Redemption  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whenever we decide to redeem any of the securities on deposit with the custodian, we will notify the depositary bank in advance. If it is
practicable and if we provide all of the documentation contemplated in the deposit agreement, the depositary bank will provide notice of the redemption to the holders. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=33,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=743858,FOLIO='29',FILE='DISK133:[18ZBZ1.18ZBZ49801]DE49801A.;9',USER='JTAYLORA',CD='10-JUL-2018;10:35' -->
<A NAME="page_de49801_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
custodian will be instructed to surrender the shares being redeemed against payment of the applicable redemption price. The depositary bank will convert the redemption funds received
into U.S. dollars upon the terms of the deposit agreement and will establish procedures to enable holders to receive the net proceeds from the redemption upon surrender of their ADSs to the depositary
bank. You may have to pay fees, expenses, taxes and other governmental charges upon the redemption of your ADSs. If less than all ADSs are being redeemed, the ADSs to be retired will be selected by
lot or on a </FONT><FONT SIZE=2><I>pro rata</I></FONT><FONT SIZE=2> basis, as the depositary bank may determine. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Changes Affecting Ordinary Shares  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ordinary shares held on deposit for your ADSs may change from time to time. For example, there may be a change in nominal or par value, a
split-up, cancellation, consolidation or any other reclassification of such ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of assets of the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any such change were to occur, your ADSs would, to the extent permitted by law, represent the right to receive the property received or exchanged in respect of the ordinary shares
held on deposit. The depositary bank may in such circumstances deliver new ADSs to you, amend the deposit agreement, the ADRs and the applicable Registration Statement(s) on Form&nbsp;F-6, call for
the exchange of your existing ADSs for new ADSs and take any other actions that are appropriate to reflect as to the ADSs the change affecting the Shares. If the depositary bank may not lawfully
distribute such property to you, the depositary bank may sell such property and distribute the net proceeds to you as in the case of a cash distribution. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Issuance of ADSs upon Deposit of Ordinary Shares  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After the completion of this offering, the ordinary shares that underlie the ADSs that are being offered for sale pursuant to this prospectus
will be deposited by us with the custodian. Upon receipt of confirmation of such deposit, the depositary bank will issue ADSs to the underwriters named in any applicable prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
the closing of this offer, the depositary bank may create ADSs on your behalf if you or your broker deposit ordinary shares with the custodian. The depositary bank will deliver
these ADSs to the person you indicate only after you pay any applicable issuance fees and any charges and taxes payable for the transfer of the ordinary shares to the custodian. Your ability to
deposit ordinary shares and receive ADSs may be limited by U.S. and English legal considerations applicable at the time of deposit. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
issuance of ADSs may be delayed until the depositary bank or the custodian receives confirmation that all required approvals have been given and that the ordinary shares have been
duly transferred to the custodian. The depositary bank will only issue ADSs in whole numbers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
you make a deposit of ordinary shares, you will be responsible for transferring good and valid title to the depositary bank. As such, you will be deemed to represent and warrant
that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The ordinary shares are duly authorized, validly issued, fully paid, non-assessable and legally obtained. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> All preemptive (and similar) rights, if any, with respect to such ordinary shares have been validly waived, disapplied or exercised. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> You are duly authorized to deposit the ordinary shares. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage or adverse claim,
and are not, and the ADSs issuable upon such deposit will not be, "restricted securities" (as defined in the deposit agreement). </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=34,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=874064,FOLIO='30',FILE='DISK133:[18ZBZ1.18ZBZ49801]DE49801A.;9',USER='JTAYLORA',CD='10-JUL-2018;10:35' -->
<A NAME="page_de49801_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The ordinary shares presented for deposit have not been stripped of any rights or entitlements. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of the representations or warranties are incorrect in any way, we and the depositary bank may, at your cost and expense, take any and all actions necessary to correct the
consequences of the misrepresentations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transfer, Combination and Split Up of ADRs  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As an ADR holder, you will be entitled to transfer, combine or split up your ADRs and the ADSs evidenced thereby. For transfers of ADRs, you
will have to surrender the ADRs to be transferred to the depositary bank and also must:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide such proof of identity and genuineness of signatures as the depositary bank deems appropriate; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide any transfer stamps required by the State of New York or the United States; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to the terms of the deposit
agreement, upon the transfer of ADRs. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
have your ADRs either combined or split up, you must surrender the ADRs in question to the depositary bank with your request to have them combined or split up, and you must pay all
applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the deposit agreement, upon a combination or split up of ADRs. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Withdrawal of Ordinary Shares Upon Cancellation of ADSs  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a holder, you will be entitled to present your ADSs to the depositary bank for cancellation and then receive the corresponding number of
underlying ordinary shares at the custodian's offices. Your ability to withdraw the ordinary shares held in respect of the ADSs may be limited by U.S. and English considerations applicable at the time
of withdrawal. In order to withdraw the ordinary shares represented by your ADSs, you will be required to pay to the depositary bank the fees for cancellation of ADSs and any charges and taxes payable
upon the transfer of the ordinary shares. You assume the risk for delivery of all funds and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the deposit agreement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you hold ADSs registered in your name, the depositary bank may ask you to provide proof of identity and genuineness of any signature and such other documents as the depositary bank
may deem appropriate before it will cancel your ADSs. The withdrawal of the ordinary shares represented by your ADSs may be delayed until the depositary bank receives satisfactory evidence of
compliance with all applicable laws and regulations. Please keep in mind that the depositary bank will only accept ADSs for cancellation that represent a whole number of securities on deposit. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
will have the right to withdraw the securities represented by your ADSs at any time except for:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Temporary delays that may arise because (i)&nbsp;the transfer books for the ordinary shares or ADSs are closed, or (ii)&nbsp;ordinary
shares are immobilized on account of a shareholders' meeting or a payment of dividends; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Obligations to pay fees, taxes and similar charges; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on deposit. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=35,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=224167,FOLIO='31',FILE='DISK133:[18ZBZ1.18ZBZ49801]DE49801A.;9',USER='JTAYLORA',CD='10-JUL-2018;10:35' -->
<A NAME="page_de49801_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
deposit agreement may not be modified to impair your right to withdraw the securities represented by your ADSs except to comply with mandatory provisions of law. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting Rights  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a holder, you generally have the right under the deposit agreement to instruct the depositary bank to exercise the voting rights for the
ordinary shares represented by your ADSs. The voting rights of holders of ordinary shares are described in "Description of Share Capital&#151;Key Provisions of Our Articles of
Association&#151;Shares and Rights Attaching to Them&#151;Voting Rights." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
our request, the depositary bank will distribute to you any notices of shareholders' meetings received from us together with information explaining how to instruct the depositary bank
to exercise the voting rights of the securities represented by ADSs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the depositary bank timely receives voting instructions from a holder of ADSs, it will endeavor to vote the securities (in person or by proxy) represented by the holder's ADSs in
accordance with the voting instructions received from such holder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities
for which no voting instructions have been received will not be voted (except as otherwise contemplated herein). Please note that the ability of the depositary bank to carry
out voting instructions may be limited by practical and legal limitations and the terms of the securities on deposit. We cannot assure you that you will receive voting materials in time to enable you
to return voting instructions to the depositary bank in a timely manner. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fees and Charges  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As an ADS holder, you will be required to pay the following fees under the terms of the deposit agreement: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="206pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Service

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Issuance of ADSs upon deposit of ordinary shares (excluding issuances as a result of distributions of ordinary shares)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Up to U.S. 5&cent; per ADS issued</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Delivery of deposited property against surrender of ADSs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Up to U.S. 5&cent; per ADS surrendered</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Distribution of cash dividends or other cash distributions (i.e.,&nbsp;sale of rights and other entitlements)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Up to U.S. 5&cent; per ADS held</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Distribution of ADSs pursuant to (i)&nbsp;stock dividends or other free stock distributions, or (ii)&nbsp;exercise of rights to purchase additional
ADSs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Up to U.S. 5&cent; per ADS held</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Distribution of securities other than ADSs or rights to purchase additional ADSs (i.e.,&nbsp;spin-off ordinary shares)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Up to U.S. 5&cent; per ADS held</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ADS Services</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Up to U.S. 5&cent; per ADS held on the applicable record date(s) established by the depositary bank</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
an ADS holder you will also be responsible to pay certain charges such as:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> taxes (including applicable interest and penalties) and other governmental charges; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the registration fees as may from time to time be in effect for the registration of ordinary shares on the share register and applicable to
transfers of ordinary shares to or from the name of the custodian, the depositary bank or any nominees upon the making of deposits and withdrawals, respectively; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> certain cable, telex and facsimile transmission and delivery expenses; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the expenses and charges incurred by the depositary bank in the conversion of foreign currency; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=36,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=798769,FOLIO='32',FILE='DISK133:[18ZBZ1.18ZBZ49801]DE49801A.;9',USER='JTAYLORA',CD='10-JUL-2018;10:35' -->
<A NAME="page_de49801_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the fees and expenses incurred by the depositary bank in connection with compliance with exchange control regulations and other regulatory
requirements applicable to ordinary shares, ADSs and ADRs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the fees and expenses incurred by the depositary bank, the custodian, or any nominee in connection with the servicing or delivery of deposited
property. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADS
fees and charges payable upon (i)&nbsp;deposit of ordinary shares against issuance of ADSs and (ii)&nbsp;surrender of ADSs for cancellation and withdrawal of ordinary shares are
charged to the person to whom the ADSs are delivered (in the case of ADS issuances) and to the person who delivers the ADSs for cancellation (in the case of ADS cancellations). In the case of ADSs
issued by the depositary bank into DTC or presented to the depositary bank via DTC, the ADS issuance and cancellation fees and charges may be deducted from distributions made through DTC, and may be
charged to the DTC participant(s) receiving the ADSs or the DTC participant(s) surrendering the ADSs for cancellation, as
the case may be, on behalf of the beneficial owner(s) and will be charged by the DTC participant(s) to the account(s) of the applicable beneficial owner(s) in accordance with the procedures and
practices of the DTC participant(s) as in effect at the time. ADS fees and charges in respect of distributions and the ADS service fee are charged to the holders as of the applicable ADS record date.
In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (i)&nbsp;distributions other than cash and
(ii)&nbsp;the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from distributions made to
holders of ADSs. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged
to the DTC participants in accordance with the procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for
whom they hold ADSs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of refusal to pay the depositary bank fees, the depositary bank may, under the terms of the deposit agreement, refuse the requested service until payment is received or may
set off the amount of the depositary bank fees from any distribution to be made to the ADS holder. Certain ADS fees and charges such as the ADS service fee may become payable shortly after the closing
of this offering. Note that the fees and charges you may be required to pay may vary over time and may be changed by us and by the depositary bank. You will receive prior notice of such changes. The
depositary bank may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise,
upon such terms and conditions as we and the depositary bank may agree from time to time. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amendments and Termination  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may agree with the depositary bank to modify the deposit agreement at any time without your consent. We undertake to give holders
30&nbsp;days' prior notice of any modifications that would materially prejudice any of their substantial rights under the deposit agreement. We will not consider to be materially prejudicial to your
substantial rights any modifications or supplements that are reasonably necessary for the ADSs to be registered under the Securities Act or to be eligible for book-entry settlement, in each case
without imposing or increasing the fees and charges you are required to pay. In addition, we may not be able to provide you with prior notice of any modifications or supplements that are required to
accommodate compliance with applicable provisions of law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
will be bound by the modifications to the deposit agreement if you continue to hold your ADSs after the modifications to the deposit agreement become effective. The deposit agreement
cannot be amended to prevent you from withdrawing the ordinary shares represented by your ADSs (except as permitted by law). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=37,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=474410,FOLIO='33',FILE='DISK133:[18ZBZ1.18ZBZ49801]DE49801A.;9',USER='JTAYLORA',CD='10-JUL-2018;10:35' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg49801_1_34"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have the right to direct the depositary bank to terminate the deposit agreement. Similarly, the depositary bank may in certain circumstances on its own
initiative terminate the deposit agreement. In either case, the depositary bank must give notice to the holders at least 30&nbsp;days before termination. Until termination, your rights under the
deposit agreement will be unaffected. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
termination, the depositary bank will continue to collect distributions received (but will not distribute any such property until you request the cancellation of your ADSs) and may
sell the securities held on deposit. After the sale, the depositary bank will hold the proceeds from such sale and any other funds then held for the holders of ADSs in a non-interest bearing account.
At that point, the depositary bank will have no further obligations to holders other than to account for the funds then held for the holders of ADSs still outstanding (after deduction of applicable
fees, taxes and expenses). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Books of Depositary  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The depositary bank will maintain ADS holder records at its depositary office. You may inspect such records at such office during regular
business hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the ADSs and the deposit agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
depositary bank will maintain in New York facilities to record and process the issuance, cancellation, combination, split-up and transfer of ADSs. These facilities may be closed from
time to time, to the extent not prohibited by law. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Limitations on Obligations and Liabilities  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The deposit agreement limits our obligations and the depositary bank's obligations to you. Please note the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We and the depositary bank are obligated only to take the actions specifically stated in the deposit agreement without negligence or bad faith. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The depositary bank disclaims any liability for any failure to carry out voting instructions, for any manner in which a vote is cast or for the
effect of any vote, provided it acts in good faith and in accordance with the terms of the deposit agreement. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The depositary bank disclaims any liability for any failure to determine the lawfulness or practicality of any action, for the content of any
document forwarded to you on our behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in ordinary shares, for the validity or worth of
the ordinary shares, for any tax consequences that result from the ownership of ADSs, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the deposit
agreement, for the timeliness of any of our notices or for our failure to give notice. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We and the depositary bank will not be obligated to perform any act that is inconsistent with the terms of the deposit agreement. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We and the depositary bank disclaim any liability if we or the depositary bank are prevented or forbidden from or subject to any civil or
criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future of any
law or regulation, or by reason of present or future provision of any provision of our articles of association or any provision of or governing the securities on deposit, or by reason of any act of
God or war or other circumstances beyond our control. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We and the depositary bank disclaim any liability by reason of any exercise of, or failure to exercise, any discretion provided for in the
deposit agreement or in our articles of association or in any provisions of or governing the securities on deposit. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=38,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=329295,FOLIO='34',FILE='DISK133:[18ZBZ1.18ZBZ49801]DG49801A.;7',USER='JTAYLORA',CD='10-JUL-2018;10:35' -->
<A NAME="page_dg49801_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We and the depositary bank further disclaim any liability for any action or inaction in reliance on the advice or information received from
legal counsel, accountants, any person presenting Shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be
competent to give such advice or information. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We and the depositary bank also disclaim liability for the inability by a holder to benefit from any distribution, offering, right or other
benefit that is made available to holders of ordinary shares but is not, under the terms of the deposit agreement, made available to you. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We and the depositary bank may rely without any liability upon any written notice, request or other document believed to be genuine and to have
been signed or presented by the proper parties. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We and the depositary bank also disclaim liability for any consequential or punitive damages for any breach of the terms of the deposit
agreement. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> No disclaimer of any Securities Act liability is intended by any provision of the deposit agreement. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pre-Release Transactions  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms and conditions of the deposit agreement, the depositary bank may issue to broker/dealers ADSs before receiving a deposit of
ordinary shares or release ordinary shares to broker/dealers before receiving ADSs for cancellation. These transactions are commonly referred to as "pre-release transactions," and are entered into
between the depositary bank and the applicable broker/dealer. The deposit agreement limits the aggregate size of pre-release transactions (not to exceed 30% of the ordinary shares on deposit in the
aggregate) and imposes a number of conditions on such transactions (i.e.,&nbsp;the need to receive collateral, the type of collateral required, the representations required from brokers, etc.). The
depositary bank may retain the compensation received from the pre-release transactions. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Taxes  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We, the
depositary bank and the custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the taxes and governmental
charges payable by holders. You will be liable for any deficiency if the sale proceeds do not cover the taxes that are due. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
depositary bank may refuse to issue ADSs, to deliver, transfer, split and combine ADRs or to release securities on deposit until all taxes and charges are paid by the applicable
holder. The depositary bank and the custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any distributions on your behalf. However, you may be
required to provide to the depositary bank and to the custodian proof of taxpayer status and residence and such other information as the depositary bank and the custodian may require to fulfill legal
obligations. You are required to indemnify us, the depositary bank and the custodian for any claims with respect to taxes based on any tax benefit obtained for you. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign Currency Conversion  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The depositary bank will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and it
will distribute the U.S. dollars in accordance with the terms of the deposit agreement. You may have to pay fees and expenses incurred in converting foreign currency, such as fees and expenses
incurred in complying with currency exchange controls and other governmental requirements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=39,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=199065,FOLIO='35',FILE='DISK133:[18ZBZ1.18ZBZ49801]DG49801A.;7',USER='JTAYLORA',CD='10-JUL-2018;10:35' -->
<A NAME="page_dg49801_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not obtainable at a reasonable cost or within a reasonable period, the
depositary bank may take the following actions in its discretion:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders for whom the conversion and
distribution is lawful and practical. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Distribute the foreign currency to holders for whom the distribution is lawful and practical. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Hold the foreign currency (without liability for interest) for the applicable holders. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Governing Law/Waiver of Jury Trial  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The deposit agreement and the ADRs will be interpreted in accordance with the laws of the State of New York. The rights of holders of ordinary
shares (including ordinary shares represented by ADSs) are governed by the laws of England and Wales. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AS
A PARTY TO THE DEPOSIT AGREEMENT, YOU WAIVE YOUR RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF THE DEPOSIT AGREEMENT OR THE ADRs AGAINST US AND/OR THE DEPOSITARY BANK. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=40,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=845307,FOLIO='36',FILE='DISK133:[18ZBZ1.18ZBZ49801]DG49801A.;7',USER='JTAYLORA',CD='10-JUL-2018;10:35' -->
<A NAME="page_dg49801_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg49801_plan_of_distribution"> </A>
<A NAME="toc_dg49801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PLAN OF DISTRIBUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may sell the securities described in this prospectus in and outside the United States (a)&nbsp;through underwriters or dealers,
(b)&nbsp;directly to purchasers, including our affiliates, (c)&nbsp;through agents or (d)&nbsp;through a combination of any of these methods. The applicable prospectus supplement or free writing
prospectus will include the following information:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the terms of the offering </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the names of any underwriters or agents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the name or names of any managing underwriter or underwriters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the purchase price of the securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the net proceeds from the sale of the securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any delayed delivery arrangements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any underwriting discounts, commissions and other items constituting underwriters' compensation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any initial public offering price; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any discounts or concessions allowed or reallowed or paid to dealers; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any commissions paid to agents. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
sale of the securities may be effected in transactions (a)&nbsp;on any national or international securities exchange or quotation service on which the securities may be listed or
quoted at the time of sale, (b)&nbsp;in the over-the-counter market, (c)&nbsp;in transactions otherwise than on such exchanges or in the over-the-counter market or (d)&nbsp;through the writing
of options. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
distribution of offered securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing at the
time of sale, at prices related to the market prices, or at negotiated prices. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sale Through Underwriters or Dealers  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If underwriters are used in the sale of any of these securities, the underwriters will acquire the securities for their own account. The
underwriters may resell the securities from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of
sale. Underwriters may offer securities to the public either through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters.
Unless we inform you otherwise in any prospectus supplement or free writing prospectus, the obligations of the underwriters to purchase the securities will be subject to certain conditions, and the
underwriters will be obligated to purchase all the offered securities if they purchase any of them. We may grant underwriters an option to purchase additional
securities to cover overallotment, if any, or otherwise in connection with the distribution. The underwriters may change from time to time any initial public offering price and any discounts or
concessions allowed or reallowed or paid to dealers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation&nbsp;M under the Exchange Act.
Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do
not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the
underwriters to reclaim a selling </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=41,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=894767,FOLIO='37',FILE='DISK133:[18ZBZ1.18ZBZ49801]DG49801A.;7',USER='JTAYLORA',CD='10-JUL-2018;10:35' -->
<A NAME="page_dg49801_1_38"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>concession
from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to cover short positions. Those activities may cause the price of the securities to
be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
underwriters who are qualified market makers on NASDAQ (or any exchange or quotation system on which our securities are listed) may engage in passive market making transactions in
our ADSs on NASDAQ in accordance with Rule&nbsp;103 of Regulation&nbsp;M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the
securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a
price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker's bid, however, the passive market maker's bid must then be
lowered when certain purchase limits are exceeded. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
dealers are used in the sale of securities, we will sell the securities to them as principals. They may then resell those securities to the public at varying prices determined by the
dealers at the time of resale. We will include in the prospectus supplement or free writing prospectus the names of the dealers and the terms of the transaction. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Direct Sales and Sales Through Agents  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may sell the securities directly, and not through underwriters or agents. We may also sell the securities through agents designated from time
to time. In the prospectus supplement or free writing prospectus, we will name any agent involved in the offer or sale of the offered securities, and we will describe any commissions payable to the
agent. Unless we inform you otherwise in the prospectus supplement or free writing prospectus, any agent will agree to use its reasonable best efforts to solicit purchases for the period of its
appointment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may sell the securities directly to institutional investors or others who may be deemed to be underwriters within the meaning of the Securities Act with respect to any sale of those
securities. We will describe the terms of any such sales in the prospectus supplement or free writing prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable
prospectus supplement or free writing prospectus indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus
supplement or free writing prospectus, including in short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out
any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale
transactions will be an underwriter and, if not identified in this prospectus, will be identified in the applicable prospectus supplement or free writing prospectus (or a post-effective amendment). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Delayed Delivery Contracts  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we so indicate in the prospectus supplement or free writing prospectus, we may authorize agents, underwriters or dealers to solicit offers
from certain types of institutions to purchase securities from us at the public offering price under delayed delivery contracts. These contracts would provide for payment and delivery on a specified
date in the future. The contracts would be subject only to those conditions described in the prospectus supplement or free writing prospectus. The prospectus supplement or free writing prospectus will
describe any commission payable for solicitation of those contracts. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=42,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=873004,FOLIO='38',FILE='DISK133:[18ZBZ1.18ZBZ49801]DG49801A.;7',USER='JTAYLORA',CD='10-JUL-2018;10:35' -->
<A NAME="page_dg49801_1_39"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Subscription Offerings  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Direct sales to investors or our shareholders may be accomplished through subscription offerings or through subscription rights distributed to
shareholders. In connection with subscription offerings or the distribution of subscription rights to shareholders, if all of the underlying securities are not subscribed for, we may sell any
unsubscribed securities to third parties directly or through underwriters or agents. In addition, whether or not all of the underlying securities are subscribed for, we may concurrently offer
additional securities to third parties directly or through underwriters or agents. If securities are to be sold through subscription rights, the subscription rights will be distributed as a dividend
to the shareholders for which they will pay no separate consideration. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may have agreements with the agents, dealers and underwriters to indemnify them against certain civil liabilities, including liabilities
under the Securities Act, or to contribute with respect to payments that the agents, dealers or underwriters may be required to make. Agents, dealers and underwriters may be customers of, engage in
transactions with or perform services for us in the ordinary course of their businesses. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=43,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=611592,FOLIO='39',FILE='DISK133:[18ZBZ1.18ZBZ49801]DG49801A.;7',USER='JTAYLORA',CD='10-JUL-2018;10:35' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di49801_1_40"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di49801_legal_matters"> </A>
<A NAME="toc_di49801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are being represented by Mayer Brown&nbsp;LLP with respect to certain legal matters of U.S. federal securities and New York State law. The
validity of the ordinary shares represented by the ADSs and certain other legal matters with respect to English law will be passed upon for us by Mayer Brown International&nbsp;LLP, our English
counsel. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di49801_experts"> </A>
<A NAME="toc_di49801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements of Adaptimmune Therapeutics&nbsp;plc as of December&nbsp;31, 2017 and December&nbsp;31, 2016, and
for each of the years in the two-year period ended
December&nbsp;31, 2017, the six-month period ended December&nbsp;31, 2015, and the year ended June&nbsp;30, 2015, have been incorporated by reference herein in reliance upon the report of
KPMG&nbsp;LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di49801_service_of_process_and_enforcement_of_judgments"> </A>
<A NAME="toc_di49801_3"> </A>
<BR></FONT><FONT SIZE=2><B>  SERVICE OF PROCESS AND ENFORCEMENT OF JUDGMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are incorporated under the laws of England and Wales. Some of our directors and officers reside outside the United States, and a substantial
portion of our assets and all or a substantial portion of the assets of such persons are located outside the United States. As a result, it may be difficult for you to serve legal process on us or our
directors and executive officers (as well as certain directors, managers and executive officers of the finance subsidiaries) or have any of them appear in a United States court. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have appointed Adaptimmune&nbsp;LLC as our authorized agent upon whom process may be served in any action instituted in any U.S. federal or state court having subject matter
jurisdiction in the Borough of Manhattan in New York, New York, arising out of or based upon the ADSs, the deposit agreement or the underwriting agreement related to such ADSs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mayer
Brown International&nbsp;LLP, our English counsel, has advised us that there is some doubt as to the enforceability in the United Kingdom, in original actions or in actions for
enforcement of judgments of U.S. courts, of civil liabilities based solely on the federal securities laws of the United States. In addition, awards for punitive damages in actions brought in the
United States or elsewhere may be unenforceable in the United Kingdom. An award for monetary damages under the U.S. securities laws would be considered punitive if it does not seek to compensate the
claimant for loss or damage suffered and is intended to punish the defendant. The enforceability of any judgment in the United Kingdom will depend on the particular facts of the case as well as the
laws and treaties in effect at the time. The United States and the United Kingdom do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards)
in civil and commercial matters. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di49801_incorporation_by_reference"> </A>
<A NAME="toc_di49801_4"> </A>
<BR></FONT><FONT SIZE=2><B>  INCORPORATION BY REFERENCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to disclose certain information to you in this prospectus by referring you to documents previously filed with the SEC that
include such information. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede
this information. We incorporate by reference the documents listed below and any future filings made with the SEC under Sections&nbsp;13(a),
13(c), 14, or 15(d) of the Securities Exchange Act of 1934 made subsequent to the date of this initial registration statement and prior to effectiveness of the registration statement and any reports
filed by us with the SEC after the date of this prospectus until the termination of the offering of the securities described in this </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=44,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=517388,FOLIO='40',FILE='DISK133:[18ZBZ1.18ZBZ49801]DI49801A.;9',USER='JTAYLORA',CD='10-JUL-2018;10:35' -->
<A NAME="page_di49801_1_41"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>prospectus
(other than information in such filings that was "furnished," under applicable SEC rules, rather than "filed").</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2017 filed with the SEC on March&nbsp;15, 2018 (the
"Annual Report"); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Quarterly Report on Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2018 filed with the SEC on May&nbsp;9, 2018; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Current Reports on Form&nbsp;8-K filed with the SEC on January&nbsp;8, 2018, March&nbsp;15, 2018, April&nbsp;12, 2018,
May&nbsp;9, 2018, June&nbsp;4, 2018, June&nbsp;20, 2018, and July&nbsp;6, 2018; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The description of our ordinary shares and ADSs contained in our registration statement on Form&nbsp;8-A, filed with the SEC under the
Exchange Act on April&nbsp;30, 2015, including any amendment or report filed for the purpose of updating such description. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may request a copy of these filings at no cost, by writing or telephoning us at the following address: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Adaptimmune
Therapeutics&nbsp;plc<BR>
Attn: Company Secretary<BR>
60 Jubilee Avenue, Milton Park<BR>
Abingdon, Oxfordshire OX14&nbsp;4RX<BR>
United Kingdom<BR>
(44) 1235 430000 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should rely only on the information incorporated by reference or provided in this prospectus or any prospectus supplement. We have not authorized anyone else to provide you with
different or additional information. An offer of these securities is not being made in any jurisdiction where the offer or sale is not permitted. You should not assume that the information in this
prospectus or any prospectus supplement is accurate as of any date other than the date on the front of those documents. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di49801_where_you_can_find_more_information"> </A>
<A NAME="toc_di49801_5"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public
over the Internet at the SEC's website located at </FONT><FONT SIZE=2><I>http://www.sec.gov</I></FONT><FONT SIZE=2> and on the investor relations pages of our website located at </FONT> <FONT SIZE=2><I>http://www.adaptimmune.com</I></FONT><FONT
SIZE=2>. You may also read and copy any document we file at the SEC's public reference room at 100&nbsp;F Street, N.E., Washington,
D.C. 20549. You can call the SEC at 1-800-SEC-0330 for further information on the public reference room. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will furnish to Citibank, N.A., as depositary bank of our ADSs, our annual reports. When the depositary bank receives these reports, it will upon our request promptly provide them to
all holders of record of ADSs or otherwise make such reports available to such ADS holders in accordance with the terms of the deposit agreement. We will also furnish the depositary bank with all
notices of shareholders' meetings and other reports and communications in English that we make available to our shareholders. The depositary bank will make these notices, reports and communications
available to holders of ADSs and will upon our request mail to all holders of record of ADSs the information contained in any notice of a shareholders' meeting it receives. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information
about us is also available on our website at http://www.adaptimmune.com. Such information on our website is not part of this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=45,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=329898,FOLIO='41',FILE='DISK133:[18ZBZ1.18ZBZ49801]DI49801A.;9',USER='JTAYLORA',CD='10-JUL-2018;10:35' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g203469.jpg" ALT="LOGO" WIDTH="561" HEIGHT="91">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>American Depositary Shares representing Ordinary Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>Prospectus  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=3><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>July&nbsp;12, 2018 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=46,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=991841,FOLIO='blank',FILE='DISK133:[18ZBZ1.18ZBZ49801]HO49801A.;2',USER='JTAYLORA',CD='10-JUL-2018;10:23' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ja49801_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ja49801_part_ii_information_not_required_in_prospectus"> </A>
<A NAME="toc_ja49801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART II<BR>  INFORMATION NOT REQUIRED IN PROSPECTUS    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja49801_item_14._other_expense__ja401996"> </A>
<A NAME="toc_ja49801_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution.    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount to be paid </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SEC registration fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FINRA filing fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Printing expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounting fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Miscellaneous</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Omitted
because the registration fee is being deferred in reliance on, and in accordance with, Rules&nbsp;456(b) and 457(r) under the Securities Act.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>These
fees are calculated based on the number of issuances and the amount of securities offered and accordingly cannot be estimated at this time.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><A
NAME="ja49801_item_15._indemnification_of_directors_and_officers."> </A>
<A NAME="toc_ja49801_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers.    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant's articles of association provide that, subject to the provisions of any relevant legislation, each of the registrant's directors
and other officers (excluding an auditor) are entitled to be indemnified by the registrant against all liabilities incurred by him in the execution and discharge of his duties or in relation to those
duties. The Companies Act 2006 renders void an indemnity for a director against any liability attaching to him in connection with any negligence, default, breach of duty or breach of trust in relation
to the company of which he is a director. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we
have been informed that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant maintains directors' and officers' liability insurance, subject to appreciable deductibles at the corporate level, for each wrongful act where corporate reimbursement is
available to any director or officer.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja49801_item_16._exhibits."> </A>
<A NAME="toc_ja49801_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A list of exhibits filed herewith or incorporated by reference is contained in the Exhibit Index which is incorporated herein by reference. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja49801_item_17._undertakings."> </A>
<A NAME="toc_ja49801_5"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;Undertakings.    <BR>    </B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
undersigned registrant hereby undertakes:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>i.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>ii.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof)
which, </FONT></DD></DL>
</DD></DL>
</DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=47,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=984998,FOLIO='II-1',FILE='DISK133:[18ZBZ1.18ZBZ49801]JA49801A.;2',USER='JTAYLORA',CD='10-JUL-2018;10:23' -->
<A NAME="page_ja49801_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>individually
or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of
securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may
be reflected in the form of prospectus filed with the SEC pursuant to Rule&nbsp;424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum
aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>iii.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such
information in the registration statement; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>iv.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that the undertaking set forth in
paragraphs&nbsp;(1)(a)(i), (1)(a)(ii) and (1)(a)(iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed
with or furnished to the SEC by the registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration
statement, or is contained in a form of prospectus filed pursuant to Rule&nbsp;424(b) that is part of the registration statement;
<BR><BR></FONT></DD></DL>
</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>That,
for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </FONT><FONT SIZE=2><I>bona fide</I></FONT><FONT SIZE=2>
offering thereof; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>c.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
<BR><BR></FONT></DD></DL>
</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
undersigned registrant hereby undertakes that, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Each
prospectus filed by a registrant pursuant to Rule&nbsp;424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus
was deemed part of and included in the registration statement; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Each
prospectus required to be filed pursuant to Rule&nbsp;424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule&nbsp;430B relating
to an offering made pursuant to Rule&nbsp;415(a)(1)(i), (vii)&nbsp;or (x)&nbsp;for the purpose of providing the information required by Section&nbsp;10(a) of the Securities Act of 1933 shall
be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of
securities in the offering described in the prospectus. As provided in Rule&nbsp;430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be
deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which the prospectus relates, and the offering of such securities at that
time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or
made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of
contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any
such document immediately prior to such effective date. </FONT></DD></DL>
</DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=48,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=145421,FOLIO='II-2',FILE='DISK133:[18ZBZ1.18ZBZ49801]JA49801A.;2',USER='JTAYLORA',CD='10-JUL-2018;10:23' -->
<A NAME="page_ja49801_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
the purpose of determining liability of a registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the
undersigned registrant hereby undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to
sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the
purchaser and will be considered to offer or sell such securities to such purchaser:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Any
preliminary prospectus or prospectus of an undersigned registrant relating to the offering required to be filed pursuant to Rule&nbsp;424;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Any
free writing prospectus relating to the offering prepared by or on behalf of an undersigned registrant or used or referred to by an undersigned registrant;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>c.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
portion of any other free writing prospectus relating to the offering containing material information about an undersigned registrant or its securities provided
by or on behalf of an undersigned registrant; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>d.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Any
other communication that is an offer in the offering made by an undersigned registrant to the purchaser.
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual
report pursuant to Section&nbsp;13(a) or Section&nbsp;15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to
Section&nbsp;15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </FONT><FONT SIZE=2><I>bona fide</I></FONT><FONT SIZE=2> offering thereof.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the
undersigned registrant, pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in
the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or
paid by a director, officer or controlling person of the undersigned registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person
in connection with the securities being registered, the applicable registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of
appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such
issue.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
undersigned registrant hereby undertakes that:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration
statement in reliance on Rule&nbsp;430A and contained in a form of prospectus filed by the undersigned registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;under the Securities Act shall be
deemed to be part of this registration statement as of the time it was declared effective; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </FONT><FONT SIZE=2><I>bona
fide</I></FONT><FONT SIZE=2> offering thereof. </FONT></DD></DL>
</DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=49,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=205603,FOLIO='II-3',FILE='DISK133:[18ZBZ1.18ZBZ49801]JA49801A.;2',USER='JTAYLORA',CD='10-JUL-2018;10:23' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="jb49801_exhibit_index"> </A>
<A NAME="toc_jb49801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXHIBIT INDEX    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description of Exhibit </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Underwriting Agreement.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>*</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1621227/000110465916127557/a16-13433_1ex3d1.htm">Articles of Association of Adaptimmune Therapeutics&nbsp;plc (incorporated by reference to Exhibit&nbsp;3.1 to our
Form&nbsp;8-K filed with the SEC on June&nbsp;16, 2016).</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>*</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1621227/000104746915003918/a2224340zex-4_1.htm">Form of certificate evidencing ordinary shares (incorporated by reference to Exhibit&nbsp;4.1 to our Registration
Statement on Form&nbsp;F-1 (file no: 333-203267)).</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>*</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1472033/000119380515000626/e613593_ex99-a.htm">Form of Deposit Agreement among Adaptimmune Therapeutics&nbsp;plc, Citibank, N.A., as the depositary bank and Holders and
Beneficial Owners of ADSs issued thereunder (incorporated by reference to Exhibit&nbsp;(a) to our Registration Statement on Form F-6 (file no. 333-203642)).</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>*</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1472033/000119380515000626/e613593_ex99-a.htm">Form of American Depositary Receipt (included in Exhibit&nbsp;2.2) (incorporated by reference to Exhibit&nbsp;(a) to our
Registration Statement on Form F-6 (file no. 333-203642)).</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>5.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>**</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2236188zex-5_1.htm">Opinion of Mayer Brown International&nbsp;LLP.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>**</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2236188zex-5_1.htm">Consent of Mayer Brown International&nbsp;LLP (included as part of Exhibit&nbsp;5.1).</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>**</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2236188zex-23_2.htm">Consent of KPMG&nbsp;LLP.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>24.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>**</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="#POA">Power of Attorney (included on the signature page to this registration statement).</A></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Previously
filed.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>**</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Filed
herewith.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>+</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
be filed, if necessary, by amendment or as an exhibit to a report filed under the Exchange Act and incorporated herein by reference.  </FONT></DD></DL>
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=50,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=647653,FOLIO='blank',FILE='DISK133:[18ZBZ1.18ZBZ49801]JB49801A.;9',USER='JTAYLORA',CD='10-JUL-2018;10:23' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="jc49801_signatures"> </A>
<A NAME="toc_jc49801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SIGNATURES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
the requirements for filing on Form&nbsp;S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Oxfordshire, England, on
July&nbsp;12, 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="49%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="46%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><B>ADAPTIMMUNE THERAPEUTICS&nbsp;PLC</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>  By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;JAMES NOBLE<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> James Noble<BR></FONT> <FONT SIZE=2><I>Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="jc49801_signatures_and_power_of_attorney_1"> </A>
<A NAME="toc_jc49801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  <A NAME="POA"></A>SIGNATURES AND POWER OF ATTORNEY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints James Noble and Adrian Rawcliffe,
and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all
capacities, to sign any and all amendments to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and
Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in
connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them or their
or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons, in the capacities indicated. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="41%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="41%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="75pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;JAMES NOBLE<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> James Noble</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>Chief Executive Officer and Director<BR>
(Principal Executive Officer)</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>July&nbsp;12, 2018</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;ADRIAN RAWCLIFFE<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Adrian Rawcliffe</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Chief Financial Officer<BR>
(Principal Accounting and Financial Officer)</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>July&nbsp;12, 2018</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;DAVID M. MOTT<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> David M. Mott</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Chairman of the Board of Directors</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>July&nbsp;12, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;LAWRENCE M. ALLEVA<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Lawrence M. Alleva</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>July&nbsp;12, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;ALI BEHBAHANI, MD<BR>



<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Ali Behbahani, MD</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>July&nbsp;12, 2018</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=51,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=821019,FOLIO='blank',FILE='DISK133:[18ZBZ1.18ZBZ49801]JC49801A.;5',USER='JTAYLORA',CD='10-JUL-2018;10:23' -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="41%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="41%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="75pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;BARBARA DUNCAN<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Barbara Duncan</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>July&nbsp;12, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;JOHN FUREY<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> John Furey</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>July&nbsp;12, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;GILES KERR<BR>



<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Giles Kerr</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>July&nbsp;12, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;ELLIOTT SIGAL, MD, PHD<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Elliott Sigal, MD, PhD</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>July&nbsp;12, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;TAL ZAKS, MD, PHD<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Tal Zaks, MD, PhD</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>July&nbsp;12, 2018</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=52,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=794477,FOLIO='blank',FILE='DISK133:[18ZBZ1.18ZBZ49801]JC49801A.;5',USER='JTAYLORA',CD='10-JUL-2018;10:23' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="je49801_signature_of_authorized_u.s._r__sig02448"> </A>
<A NAME="toc_je49801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF THE REGISTRANT    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the Securities Act, the undersigned, the duly authorized representative in the U.S. of Adaptimmune Therapeutics&nbsp;plc, has
signed this registration statement or amendment thereto on July&nbsp;12, 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="38%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2>ADAPTIMMUNE&nbsp;LLC</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;JAMES NOBLE<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Name:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>James Noble</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Title:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><I> Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=53,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=680480,FOLIO='blank',FILE='DISK133:[18ZBZ1.18ZBZ49801]JE49801A.;4',USER='JTAYLORA',CD='10-JUL-2018;10:23' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>a2236188zex-5_1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#18ZBZ49801_2">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="kg49801_exhibit_5.1"> </A>
<A NAME="toc_kg49801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;5.1    <BR>    </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g85507.jpg" ALT="GRAPHIC" WIDTH="147" HEIGHT="112">
  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Adaptimmune Therapeutics&nbsp;plc<BR>
60 Jubilee Avenue<BR>
Milton Park<BR>
Abingdon<BR>
Oxfordshire<BR>
OX14&nbsp;4RX</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>12&nbsp;July 2018<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>Our
ref: 20456/15489949 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Dear
Sirs </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Registration Statement on Form&nbsp;S-3  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Background  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have acted for Adaptimmune Therapeutics&nbsp;plc, a public limited company incorporated under the laws of England and Wales (the </FONT> <FONT SIZE=2><B>"Company"</B></FONT><FONT
SIZE=2>), as its legal advisers in England in connection with the registration statement on Form&nbsp;S-3 (the </FONT><FONT SIZE=2><B>"Registration
Statement"</B></FONT><FONT SIZE=2>) to be filed on or about 12&nbsp;July 2018 by the Company with the U.S. Securities and Exchange Commission under the U.S. Securities Act&nbsp;of&nbsp;1933, as
amended (the </FONT><FONT SIZE=2><B>"Securities Act"</B></FONT><FONT SIZE=2>), and the rules and regulations promulgated thereunder (the </FONT><FONT SIZE=2><B>"Rules"</B></FONT><FONT SIZE=2>). The
Registration Statement relates to the offering, issuance and sale by the Company from time to time of an indeterminate numbers of ordinary shares of &pound;0.001 each in the Company
(</FONT><FONT SIZE=2><B>"Ordinary Shares"</B></FONT><FONT SIZE=2>), as may from time to time be offered and sold at indeterminate prices pursuant to the Registration Statement. The Ordinary Shares
are to be offered or sold in the form of American Depositary Shares (</FONT><FONT SIZE=2><B>"ADSs"</B></FONT><FONT SIZE=2>). Each ADS represents 6 Ordinary Shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
understand that the Ordinary Shares are not, nor are intended to be, admitted to trading on any market or exchange, or otherwise listed, in the United Kingdom. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the Registration Statement, we have been asked to provide an opinion on certain matters, as set out below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Examination and enquiries</B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
the purpose of giving this opinion, we have examined:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a
copy of the Registration Statement (excluding its exhibits and any documents incorporated by reference into the Registration Statement); and </FONT></DD></DL>
</DD></DL>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g970489.jpg" ALT="GRAPHIC" WIDTH="663" HEIGHT="102">
  </B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="2",CHK=795024,FOLIO='blank',FILE='DISK133:[18ZBZ1.18ZBZ49801]KG49801A.;18',USER='JTAYLORA',CD='12-JUL-2018;09:44' -->
<A NAME="page_kg49801_1_2"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a
certificate dated 12&nbsp;July 2018 signed by the company secretary of the Company (the </FONT><FONT SIZE=2><B>"Officer's Certificate"</B></FONT><FONT SIZE=2>)
relating to certain factual matters and having annexed thereto copies (certified by the company secretary as being true, complete, accurate and up-to-date in each case) of the following
documents:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(A)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
Company's certificate of incorporation, certificate of incorporation on re-registration, memorandum of association and articles of association; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(B)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>minutes
of a meeting of the board of directors of the Company held on 11&nbsp;July 2018 at which it was resolved, inter alia, to approve the filing of the
Registration Statement with the U.S. Securities and Exchange Commission.
<BR><BR></FONT></DD></DL>
</DD></DL>
</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
the purpose of giving this opinion, we have:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>on
12&nbsp;July 2018 made an online search of the register kept by the Registrar of Companies in respect of the Company (the </FONT><FONT SIZE=2><B>"Company
Search"</B></FONT><FONT SIZE=2>); and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>made
a telephone enquiry in respect of the Company of the Central Index of Winding Up Petitions on 12&nbsp;July 2018 at 11:35&nbsp;a.m. (BST) (the </FONT> <FONT SIZE=2><B>"Telephone Search"</B></FONT><FONT SIZE=2>, and, together with the Company Search,
the </FONT><FONT SIZE=2><B>"Searches"</B></FONT><FONT SIZE=2>).
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
the purposes of giving this opinion, we have only examined and relied on those documents and made those searches and enquiries set out in paragraphs&nbsp;2(a)
and (b)&nbsp;respectively. We have made no further enquiries concerning the Company or any other matter in connection with the giving of this opinion.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(d)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>We
have made no enquiry, and express no opinion, as to any matter of fact. As to matters of fact which are material to this opinion, we have relied entirely and
without further enquiry on statements made in the documents listed in paragraph&nbsp;2(a). </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Assumptions</B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>In
giving this opinion we have assumed:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
genuineness of all signatures, seals and stamps;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>that
each of the individuals who signs as, or otherwise claims to be, an officer of the Company is the individual whom he or she claims to be and holds the office
he or she claims to hold;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(iii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
authenticity and completeness of all documents submitted to us as originals;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(iv)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
conformity with the original documents of all documents reviewed by us as drafts, specimens, pro formas or copies, and the authenticity and completeness of all
such original documents;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(v)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>that
the meeting referred to in paragraph&nbsp;2(a)(ii)(B) (</FONT><FONT SIZE=2><I>Examination and enquiries</I></FONT><FONT SIZE=2>) was duly convened,
constituted and held in accordance with all applicable laws and regulations; that in particular, but without limitation, a duly qualified quorum of directors was present throughout the meeting and
voted in favour of the resolutions; and that each provision contained in the Companies Act 2006 or the articles of association of the Company relating to the declaration of directors' interests or the
power of interested directors to vote and to count in the quorum was duly observed;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(vi)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>that
the minutes referred to in paragraph&nbsp;2(a)(ii)(B) (</FONT><FONT SIZE=2><I>Examination and enquiries</I></FONT><FONT SIZE=2>) are a true record of the
proceedings of the relevant meeting and that each resolution recorded in those minutes has not been amended or rescinded and remains in full force and effect; </FONT></DD></DL>
</DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=2,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="2",CHK=229560,FOLIO='2',FILE='DISK133:[18ZBZ1.18ZBZ49801]KG49801A.;18',USER='JTAYLORA',CD='12-JUL-2018;09:44' -->
<A NAME="page_kg49801_1_3"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(vii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>that
the directors of the Company acted in accordance with ss171 to 174 Companies Act 2006 in approving the resolutions recorded in the minutes referred to in
paragraph&nbsp;2(a)(ii)(B) (</FONT><FONT SIZE=2><I>Examination and enquiries</I></FONT><FONT SIZE=2>); and that all actions to be carried out by the Company pursuant to those resolutions are in its
commercial interests;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(viii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>that
there are no provisions of the laws of any jurisdiction outside England and Wales that would have any implication for the opinions we express and that,
insofar as the laws of any jurisdiction outside England and Wales may be relevant to this opinion letter, such laws have been and will be complied with;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ix)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>that
each consent, licence, approval, authorisation or order of any governmental authority or other person which is required under any applicable law in connection
with the transactions contemplated by the Registration Statement, has been or will have been obtained and is or will be in full force and effect;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(x)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>that
the Company is and will at all relevant times remain in compliance with all applicable anti-corruption, anti-money laundering, anti-terrorism, sanctions,
exchange control and human rights laws and regulations of any applicable jurisdiction;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(xi)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>that
no agreement, document or obligation to or by which the Company (or its assets) is a party or bound and no injunction or other court order against or affecting
the Company would be breached or infringed by the performance of actions to be carried pursuant to, or any other aspect of the transactions contemplated by, the Registration Statement;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(xii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>that
the information disclosed by the Searches is true, accurate, complete and up-to-date and that there is no information which, for any reason, should have been
disclosed by those Searches and was not;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(xiii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>that
the Company and each party to whom any Ordinary Shares are offered, issued and/or sold will comply with all applicable laws (for the avoidance of doubt, as
in force at all relevant times) with respect to anything done by any of them in relation to the Ordinary Shares, including without limitation the Financial Services and Markets Act 2000,
Directive&nbsp;2003/71/EC of the European Parliament (as implemented in the United Kingdom) and Regulation (EU) No.&nbsp;596/2014 of the European Parliament;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(xiv)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>that
the Ordinary Shares will be duly allotted by the board of directors of the Company in accordance with the Company's articles of association (for the avoidance
of doubt, as in force at all relevant times) and pursuant to (A)&nbsp;a valid authorisation under s551 Companies Act&nbsp;2006 and (B)&nbsp;a valid power under s570 Companies Act 2006 to allot
the Ordinary Shares as if s561 of that Act did not apply to the allotment; and that those sections of the Companies Act&nbsp;2006 will continue in force unamended at all relevant times;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(xv)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>that
as at each date on which the Company allots and/or issues any Ordinary Shares, the documents examined, and the results of the searches and enquiries made, as
set out in paragraph&nbsp;2 (</FONT><FONT SIZE=2><I>Examination and enquiries</I></FONT><FONT SIZE=2>), would not be rendered untrue, inaccurate, incomplete or out-of-date in any relevant respect
by reference to subsequent facts, matters, circumstances or events;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(xvi)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>that
as at each date on which the Company allots and issues any Ordinary Shares, the Company will have received the aggregate consideration payable for those
Ordinary Shares as "cash consideration" (as defined in s583(3) Companies Act 2006), such aggregate consideration being not less than the nominal value of those Ordinary Shares; and that s583 Companies
Act 2006 will continue in force unamended at all relevant times; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(xvii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>that
there is and will be no fact or matter (such as bad faith, coercion, duress, undue influence or a mistake or misrepresentation before or at the time any
agreement or </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=3,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="2",CHK=728011,FOLIO='3',FILE='DISK133:[18ZBZ1.18ZBZ49801]KG49801A.;18',USER='JTAYLORA',CD='12-JUL-2018;09:44' -->
<A NAME="page_kg49801_1_4"> </A>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>instrument
is entered into, a subsequent breach, release, waiver or variation of any right or provision, an entitlement to rectification or circumstances giving rise to an estoppel) and no additional
document between any relevant parties which in either case would or might affect this opinion and which was not revealed to us by the documents examined or the searches and enquiries made by us in
connection with the giving of this opinion.  </FONT></P>

</UL>
</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>In
relation to paragraph&nbsp;3(a)(xii), it should be noted that this information may not be true, accurate, complete or up-to-date. In particular, but without
limitation:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>there
may be matters which should have been registered but which have not been registered or there may be a delay between the registration of those matters and the
relevant entries appearing on the register of the relevant party;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>there
is no requirement to register with the Registrar of Companies notice of a petition for the winding-up of, or application for an administration order in
respect of, a company. Such a notice or notice of a winding-up or administration order having been made, a resolution having been passed for the winding-up of a company or a receiver, manager,
administrative receiver, administrator or liquidator having been appointed may not be filed with the Registrar of Companies immediately and there may be a delay in any notice appearing on the register
of the relevant party;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(iii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
results of the Telephone Search relate only to petitions for the compulsory winding up of, or applications for an administration order in respect of, the
Company presented prior to the enquiry and entered on the records of the Central Index of Winding Up Petitions. The presentation of such a petition, or the making of such an application, may not have
been notified to the Central Index or entered on its records immediately or, if presented to a County Court or Chancery District Registry, at all; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(iv)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>in
each case, further information might have become available on the relevant register after the Searches were made. </FONT></DD></DL>
</DD></DL>

<P style="font-family:times;"><FONT SIZE=2>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Opinions</B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>On
the basis of the examination and enquiries referred to in paragraph&nbsp;2 (</FONT><FONT SIZE=2><I>Examination and enquiries</I></FONT><FONT SIZE=2>) and the
assumptions made in paragraph&nbsp;3 (</FONT><FONT SIZE=2><I>Assumptions</I></FONT><FONT SIZE=2>) and subject to the qualifications set out in paragraph&nbsp;5
(</FONT><FONT SIZE=2><I>Qualifications</I></FONT><FONT SIZE=2>), we are of the opinion that:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
Company is a public limited company duly incorporated under English law;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
Company Search indicates that the Company is validly existing and does not reveal any order or resolution for its winding up or any notice of the appointment of
a receiver, administrative receiver or administrator in respect of it or any of its assets. The Telephone Search does not reveal that any petition for the winding-up of the Company has been presented,
that any application for administration of the Company has been made or that any notice of appointment, or of intention to appoint an administrator, has been filed in respect of the Company; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(iii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>in
connection with a relevant issuance, upon receipt of the aggregate consideration for Ordinary Shares and entry of the names of the appropriate persons in the
Company's register of members, the relevant Ordinary Shares will be validly issued, fully paid and no further amount may be called thereon.
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
the purpose of paragraphs&nbsp;4(a)(i) and (ii):
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>"duly incorporated"</B></FONT><FONT SIZE=2> means that the requirements of the Companies Act in force at the date of incorporation of the
Company in respect of registration and all matters precedent and </FONT></DD></DL>
</DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=4,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="2",CHK=690544,FOLIO='4',FILE='DISK133:[18ZBZ1.18ZBZ49801]KG49801A.;18',USER='JTAYLORA',CD='12-JUL-2018;09:44' -->
<A NAME="page_kg49801_1_5"> </A>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>incidental
to it have been complied with by the Company and that the Company is authorised to be registered and is duly registered under that Act; and  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>"validly existing"</B></FONT><FONT SIZE=2> means that the Company is subsisting at the date of this opinion and has not been struck off the
register kept by the Registrar of Companies, dissolved or ceased to exist by reason of any merger, consolidation or limitation on the duration of its existence.
<BR><BR></FONT></DD></DL>
</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
the purpose of paragraphs&nbsp;4(a)(iii), a </FONT><FONT SIZE=2><B>"relevant issuance"</B></FONT><FONT SIZE=2> means an allotment and issue of Ordinary Shares
in accordance with the assumptions made in paragraph&nbsp;3 (</FONT><FONT SIZE=2><I>Assumptions</I></FONT><FONT SIZE=2>) and in particular but without limitation those assumptions in
paragraphs&nbsp;3(a)(xiv) and (xvi).
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(d)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
opinion is strictly limited to the matters expressly stated in this paragraph&nbsp;4 and is not to be construed as extending by implication to any other
matter. </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Qualifications</B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
opinions set out in paragraph&nbsp;4 (</FONT><FONT SIZE=2><I>Opinions</I></FONT><FONT SIZE=2>) are subject to the qualifications set out in the remainder of
this paragraph&nbsp;5.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>We
express no opinion as to matters of United Kingdom taxation or any liability to tax (including, without limitation, stamp duty and stamp duty reserve tax) which
may arise or be incurred as a result of or in connection with the Ordinary Shares or the transactions contemplated by the Registration Statement, or as to tax matters generally.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
opinion set out in paragraph&nbsp;4(a)(iii) (</FONT><FONT SIZE=2><I>Opinions</I></FONT><FONT SIZE=2>) relates only to Ordinary Shares offered or sold from
time to time pursuant to the Registration Statement that are new Ordinary Shares issued by the Company from time to time following the date of the Registration Statement. We express no opinion in
respect of any securities of the Company existing at the date of this opinion which may be offered or sold from time to time pursuant to the Registration Statement. </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Law</B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
opinion and any non-contractual obligations arising out of or in connection with this opinion shall be governed by, and construed in accordance with, English
law.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
opinion relates only to English law (being for these purposes, except to the extent we make specific reference to an English law "conflict of law" (private
international law) rule or principle, English domestic law on the assumption that English domestic law applies to all relevant issues) as applied by the English courts as at today's date, including
the laws of the European Union to the extent having the force of law in England.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>We
do not undertake or accept any obligation to update this opinion to reflect subsequent changes in English law or factual matters.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(d)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>We
express no opinion as to, and we have not investigated for the purposes of this opinion, the laws of any jurisdiction other than England. It is assumed that no
foreign law which may apply to the matters contemplated by the Registration Statement, any document or any other matter contemplated by any document would or might affect this opinion. </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not admit that we are in the category of persons whose consent
is required under section&nbsp;7 of the Securities Act or the Rules. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>Yours
faithfully </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>/s/ Mayer Brown International&nbsp;LLP</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=5,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="2",CHK=293782,FOLIO='5',FILE='DISK133:[18ZBZ1.18ZBZ49801]KG49801A.;18',USER='JTAYLORA',CD='12-JUL-2018;09:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="18ZBZ49801_2">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kg49801_1">Exhibit 5.1</A></FONT><BR>
</UL>
<!-- SEQ=,FILE='QUICKLINK',USER=JTAYLORA,SEQ=,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>a2236188zex-23_2.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#18ZBZ49801_3">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="ki49801_exhibit_23.2"> </A>
<A NAME="toc_ki49801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;23.2    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ki49801_consent_of_independent__ki402326"> </A>
<A NAME="toc_ki49801_2"> </A></FONT> <FONT SIZE=2><B>  Consent of Independent Registered Public Accounting Firm    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We consent to the use of our report incorporated by reference herein and to the reference to our firm under the heading "Experts" in the
prospectus. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>/s/
KPMG&nbsp;LLP </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Reading,
United Kingdom<BR>
July&nbsp;12, 2018 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="3",CHK=389251,FOLIO='blank',FILE='DISK133:[18ZBZ1.18ZBZ49801]KI49801A.;9',USER='MTITUSS',CD='10-JUL-2018;10:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="18ZBZ49801_3">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ki49801_1">Exhibit 23.2</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ki49801_2">Consent of Independent Registered Public Accounting Firm</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=JTAYLORA,SEQ=,EFW="2236188",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="3" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g203469.jpg
<DESCRIPTION>G203469.JPG
<TEXT>
begin 644 g203469.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ \35),3%]'4D%02$E#4SI;041!4%1)
M34U53D5?3$E-251%1%U!1$%05$E-355.15\T0U],3T=/+D504__; $,  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$(
M %L",0,!(@ "$0$#$0'_Q  ?  $  @(" P$!            "0H("P$' @4&
M! /_Q !>$   !@(! @,$ P@)# X+   ! @,$!08'"  )$1(3% H5(3$648$7
M.6%Q>)&RMR(C.$%VH;&UMADD,C-"4EAR<Y+6\!HE-C<Z5E=WEYBSP<?1)B<H
M0T5&>966HM+_Q  = 0$  @(# 0$             !@<%" (#! $)_\0 31$
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M\L#[PH$@F/XY@S'BH]GK:GON0G#QL3:>;Q3+-2O5F"&L5@3X?$)>I06V>2X
MOI;4-@5<\2(SS0&P!L1F75S)<1EK!MYEJ'=H@Z::CIB?SHN?C"J%.O7;? KF
M]V6JM/0+X74-,(K(D-X7<>I'R:#5^WOM=-7J48KZCN*9*'F8V!JV<JO"^ES#
MAQP?WA%O8E\/NL]OJ",KYRUAQO83+@R=-GH.WM:D'1JS91<>=%RLY7[ZS'1[
MBM;&,KM3J_#+H806D$AR?BUB@LNAAU9\9-!"VU9<RR[@V-9"14(UE8=P'_H$
M^=-5V+E6JO!:5N#G638O(^IV<:#GC%KPS>UT27*Y4BUEUD(RUU]T)&]FI$^1
M(Q16@[7%@I&O"F 3,W/H9AMX'\4R53N_9=;U+OOIP;)KDK1L-=1A0N$(5[E>
M[7 3/!9F!F?),R0PIDFR*TM7<IM.LQB[-;X?+YWMEGRQ.6@V8IK!FU7B2;7;
M6:7C&2QTSQPR(&?(8$9; '7L +0 DR:=9GIG$T@RLRR=BB.7+K3F.;D25=B0
M%G!,578$5)5_C5R[.4W>OO6A7DMCI=RJ=Y[HCY>ONU%EJ^W=R&._2NWCE=&-
MJ*O<I%^L7#V0UHS'V<8D1\;8:<_D0".N::)@,!9;'$J[&Q-UTRE67@CV6&!0
MA);QIW?<C5##_5$T+78LCH.*/L3BJ/M%'F'22:TC2+>NS+)U:8 XHJ':S]#N
M39-I*E;@4YU(Z6C3G,U=K$4UP%SI]DQ];[70+M$J0UNI5BG:?;8-R7L>-L-=
MDG4+.QR@?W2:+]HY23.'<J[<4UB")%2B/7VIV,>Y>F9W1MS WY?#K+#98;,1
M%NS2.6*J73\_Q?>-"Q7-+G<2Q=JM5ML/WOYZY;OB)T_8<9L>O$*L?D#'(T"3
M_@$V ];'UQX^)J65-%BU_ $ASJXCZU?.UL:NFSUL@\:.$'31RBDY;.FRJ:[9
MPW63*JBX072,=)5!9(Y%454SF(HD<IRF$I@'E4;V@/=YU)ST1I)CV9.G#PA(
M>ZYY68K&*$E-."HRU!QZ[,4A0.TBFAFUXGF@**I+/W=226*!V#E+DB/2'W.C
M[]TQ6&0<BS NY35*OW+'^1GSERD#M: Q- $L-6DG!E>P^;(8V<5UL9PL)O52
M#1V;N93Q%Y2YRSD^SYMRA?\ +US7%Q:\G7"=N\X8W8"H/;$^4?$CD2AV*DTA
MVBC6'8HE I$&4>W2*4H$[<_,COPV[I;+^EL.1R!Y&]C[;0B1@Z%!L Q@<\$*
M[_FB5\\PRJ;1GX+K]:/L(Z)0[A;27<F]6%^(U''XZ_C$MB#"=ERXL*B1P0R+
M"PR*]VQ/'B:,C]W/&?U?$]F:G:R7_;[.]*P5CLJ;:5M+EP[FK$\047BJ94(D
MA'-EM\P4G;QMHEF<B3)F91(TQ.O8B$2435DBJ)WQ8MIJ]TL]16R#QZVHV)<7
M1?=W(.").[=D*ZR@"==P*"7ENK9D>^2Q#>0S;E\!.Y&C8L96H8OH, >@MJ6T
MP[K(ML)985-'(VQ:Q96*>.D"ED8O$$0X.WI<6B<_=1NWM#Y.0N[@$_*]8WDX
M '13^[6HIP:]9O>*2VGV3EL8U6736P?K[.3%4JB+!7Q,;9?&Q?=5ZOCHZ:JB
M+[R7Z+VHU94HF1;04>^?-! UD>":"X8:O;[41V&PE;M@SJQ&@IL3^J0T8:E<
MQ'!BH5P-NWXR$L,D5BD2$#ZN7?G9?[4??%G:W%Y"S1[7]N;#7[+<IF,1>OTV
MS2R%I93!H;=;<-N$P<,AZZU=>1RZU-6RRB<>M\>H[G/>ZWJJ6UXM2\01+XZU
M)PO!R2ZM=C$TS]FLO;W) ;EN]R.F4AUI:1;A%Q"@G;5>+C$?4.G^*.',&9CV
M#MZ-&PGCBVY,MAP266C:M&*/"1;94WA3D9^56,WA:W&"8!#WG8)*,8F$!*FN
M=0/ .5?3NT"O>^V7U:G&NI"I8LIR3:4RMDM"/(\+7V#OS?=5=@B.O"P>W6T'
M073B6KDRC>*CF[^QR+5TT8H,)&Z6NXTNZ6NO*0+?13"F+X<Z;=,J3=61N&0[
M4+41#Q)MTG5IR/>Y8B1E%53E?.4T"F44-&0S3NUCN"U3);D=G9-BR9T\7Y&;
M\C9)<-L0J9A@U_9(HK5D<2'N(?0HH]24L\&0NUNY/>K4NPB,3VF[5:@C.[C*
MD(QVJXI-@Z>+.X(%59EOI(;D<IE\EY!9BBMDY*Z!_6W[U?WU3M]-])7!FW6M
MVN*V'MIB4U%G6)OSL1QT';E;=9:U4Y4BSR6J%E=M6"5?2CX69$SFJ$AY:9%N
MQE'L4LJW9QD84\IO*LF4/:1$R6QJTP[KD!J&UFF@2MFR?;%6UE?UM.10&5>1
ME/J+=TQBY 88KQ6/0D;7(^%Z+<'B %(J@>T) 3L79X.&LD&\1D86P14=-P\@
MW'Q(/HJ69HR$<\1-_=).F3E!<AOWRG 0Y>.JY; VZDXK!Y%N15A55ZY-?[9;
MZS]D)_6M2B'",*)8FH)6(@ Q/$CS^<_>C2>Y>$S0;IW&U6EJUON!<R6414QL
MTQJ?5)^D9D.:=6]D#Q[FG=39:BX^++'/<PA@X9 ^WXXXY*NJ6Z<@^WCZXV%-
M*\_3&OKK$M_RO9:O7Z]*6R6J5@J$-$0,S9&BDJSJZP3SDKIS*-H)6)EGZB)"
MMVQ)EHU'Q.4G)4Y6]B,VU+6_!V4LZWE7RZOBZES5ND42G*FO)*1S4WNR"8F,
M D-)6&748048F;X*OY%NG_=<UW>+L!;!]1>][>9HC &9N%*H60=F<B+@W6<!
M.V*0F3R$?CV#*F?N26G6B=A0JR >8DA&T\&943 9N4+Q[-Z#@-F+.;!N9>G5
M<(NK4)AV'TUNRN0L)57&;"" _! %$- 2B9;<J>7(2436O<':<IAHQF*UZ/9F
M\B;K$ *EV&+HU5,-DPEHF$DXQGP*1G\%>Q$1Y<3&PMU>V(H^U^!,9; 8\%PE
M6LD5Q"83C'RC=64KTL@LO&V&K3!FASM_?%9GF4C"20H&%!1RR.LW$S=5$YN_
M>5%/9L]NTV,SD[3&TRI?1SZ3K-.&P<N#]C2+=!FRR;6(],Y#@ .V!8.[M&J9
MT@\:%L=B10YU#$MU\@W<;46:1N&8P$B?TB7_ %.+:R9*78NW'NI%)S_A#4LI
MK/./B;-=\1QQQU)=1SP[)K]#*<C]0:_3= >(A=U' 6(@8_8$RB'+&?F$M7/[
M^G'''(/U)>G'.!,4O]D8 [_+N(!W_/P!BF^1BCV^?80'^3CIUA3U%L_7S5S2
MW/.>\8IU]6]XXK4/+5TEIC',S &=/KE6H)<)*,:240X=I QEG0ID2D6HE< B
MJ)S%(9,\?717ZBVPN_"FQY<[-\<H!BL^*R5?Z U23K(G"XA?1F!E?>-GL7K>
MWT<CO1^3Z3T_=SX_/\TOE9,=:/[V'MO_  'K?ZRZ/R'?V8'^W;L?Y; 7Z.7.
M7?K^ PMGL9O.POQM5N;Q^Q4*M+)&OFU6KLLZT#$J9S^$"&W9B8X^8<?]/5;9
M;*9%/<O6<6JX\,=;Q-IUFF)\(<T$Y<A88?O*"2F>>?\ DP_HZMF<<<X$0#YB
M ?C$ _EY2'5D]<\<X Q1^1BC^(0'^3G/'3IQQQW ?D(#QTZ<<X$0 .XB !]8
MCV#\X\X Y!$  Y1$?D & 1'\0=_CQTZ\N...X!\Q[<=.NALD;3:T8=L'T4RS
ML%A;&5G"+;38UV_9.IM1F_<SQ1VDTE?=<],,7ONYTHQ>IMWOD^G6.T<E34,*
M"@%[MCY!A+,&4I%O6LC&R31L_CY!BX2=LGS%X@FY:/&CI QT7#5TW527;KI'
M,FLBH11,QB&*(T2?:.BD-OV(B4AO_9CQS\1*4P_"8RF(?$0$?P]N79, " 8+
MPR'< _\ 51C?X=P_XE0?+,VW0ZNN:;HVSIR%BR_;:UNQ8JM4L%4YKA4(12P)
MDV04V2B9.(F/&./SGJ&8#9WYC8-EPS*J4JP3DK2X&&3'PPW#,L$H@0F/7$QX
MS//,]=O"/8!$?D'Q'D0VS?6JT^U5V-4UMR$CDR3L4&X@6F0;?5*Q&2=+QVYL
MC!A*L$9QRZGX^;E5&$3)L)>PEK$-+^YF#HI3"ZD474>WEX^ @(? 0^0_;R'W
M9WHGZA[4[)&V2OKS),/-SKF%>9(I=5L49'4[)+JOL6$6R<3)7<(^GX-5]$QC
M")L!JK,Q'O=@U(< 9R2KJ17P>E?H5]Z6?T[G,1B?NVU]+]R^'U/WGY*^G]GG
M_P EZOJ/#X\/J?I_?Q7]L]9/9/TCBDG]&(HS>^L1[_K^?5]'P?M\./\ &\_5
M)_XT)]OJB6^'4OC5RW>MT';1=%RU=(I.&SENH19!PW73*JBNBJF)B*HK)'(H
MDH0PE.0Q3%$0$.?WY^=JV;,6S=FT12;-6J*39LW1(5)%!!!,J2""*90 B:22
M1")ID* %(0I2@'8.?H[@/R'OR(3QS/'/'/QS^?'[N?Z^L_'/$<\<\1SQ^7/[
M^.?GC^CIQSQ$Q0'L)B@/U"( /YA'G(&*;XE$!#ZP$!_DY\Z^]<\<<X$Q2_V1
M@#O\NX@'?\_'3KGCG &*;OX3 /;Y]A >WX^W.>.G3C@1 /F(!^/CCITXYXB<
M@"("<H"'S 3  A^,._PYR @(=P$! ?D(#W ?M#CIUSQQSQ$Y 'L)B@/U"8 '
M\PCQTZ\N.< 8IOB40$/K 0'^3G/'3IQSCN'UA^?G/'3IQQQW /F/;CITXX[@
M/R'OSCN'UA^?CIUSQQ\OGSP\Q/\ OR?YQ?\ SXZ=>?''''3IQQSQ$Q0'L)B@
M/U"( /YA'CIUY<<X Q3?V)@'\0@/\G.>.G3CCCCIU1(WQZ//48C;1EW:2V0>
M.<V+W2SV/)F0$<&S\S*SD$,HHK(R;AI2[16JO-2\3$()E;E2K(34H1DV36+$
M"F14R4(U'N]LQQ;ZMD&@6.4J=SILW'6:IVF#<BVE(.;C5B.6$DP6#N0QB'*!
M5VRQ5&<@S47CY!!RQ=.&ZFUO,4#!V'\8#\.X"'Q 0[]P[@/Q#X?/D 6<?9YM
M4<S9?R/EEOD_,N.AR-;)2XO*72DL>%J<%+3JA7DTE (RM+?OFD>^ESOI8K%1
MXLBR<2#ALS!)DFW01V[[>?:'IC2L8;?ZM9=)%-5;'6,7CC-3:P -4L=<H";5
MR$(\84Q8K5*@-3ED4B94+M?:>Q]0K(:NY[;#;!-MJNVP%BW$7M&VBT4++REO
M,F)$3(,A8LXB)@<W.GKM15NH]I1%VV]P</(3<K&6##VP%+%$HPKFTM(M*-M;
M=)B"OC2KEW@)9E8HMJ8X"UCI\(\%3+1YU>4*]U-<WVIFT^;=?G0/#,,>75ZU
MJ3M\/B=2F/YI!O8L?RJRGC4\Y=U496*3>+"<QE)!N]\8@H!@"^[T]^G%CWIX
M1&4(''&3,EWZ(RA+UB>D&.02U0J4++5N.DHD7D-]&:_!""DNP>-&\GZSU7B+
M$1_D>2)5?,Q]W;Z*F =WL[O\^W7)V6J):)6IU:K2D9124DT,_"IIR#9A+KC8
MJM-/QDE6#QO'N!*[*W]-&L@31(<JIE(KVZ[CZEH6_P"V%3M71T/-+EM!8T[!
MM1:%J;%,(JS,M *H6,A1@RB28L4F93Q$QFMLU+/;/JV!BQ706SX\Q79*;"8!
MJ# U/.7Q/K(G$JK9D8F( R:(Q',]8C^S5YV=W#7/-. )9VHX6POD5C::T1=8
MY_3T[+C%Z]5C69#*&!-NQNM9M3XR94TTTC3Q?")A4$"PD==_#3+$747R5)Q3
M8C2)S14Z1F=%!,/"0DQ.M'U3MBA?EXS/K)2WTPL<"AW<2RO?N8#"-K7I^]*/
M%'3TO&0KKC3*N5KLID>IP]5FH:^%IQ8M D%-+S,;*,_HU6X-SZ]$[Q^T'U*S
MA#TSQ0"I$4#QF_+O_P!)/"W4&R+1LEY&R-E"B3M&I+NB-4J"%1.TE(A>?<V)
MNI(ELM<G%2N6#QZ^3;"S4;)F1=J@N14Q4C)]N$[EZE@>]&>VVE9MAJN?I."R
M0TG0_P"JLUJ5IQ%4X\YD\Q5,_.(^!>1<P,E$\,CI^=R?;O%X*PE)9O%V5$@9
MLJ]?H4ZPA4>_GPB!H/$?'G\U#'',1U3[T^V/>8STMZC6%2.5"#F.KZ_!") X
M*F"3EQDU6GW8Z*1S@)SO:5(D0<E0(8ZB+1$Z_9!L)B8J4BHO<AWBG4*..*<C
M?;?6*4Q4*'<4G=PGX^NH+ '<O<4%),JP!XB]Q3[ (=^X6T8OV;36:(*](UV&
MV+\J000;O$CH8J,19-LZ3>MP$0H *%\ERD14OEJ$$PAX5!.0?!SMO#'0-UUP
MSEW&.78O,N;+#)XOO=8OT9!SR./BPLK)5640EX]G*#&U!D_!D=XV0.MZ1VW7
M$$P JH )@'5+[2N,CN=W;=M.JP+M=MXW!H>RS_$7!8K+^GOE],WAA<K!9^41
M^LF>(Y*)Z_27[&?>G2NQ78;)ZEM=B[6WEN>V7+U$5,<[(56K?0I!A%'>3!($
M9L(:) <Q"?,B/@2YG/[;[(;'3+0C+%II:)F:>'L*HTW'B"9TT3,98T=&8WH(
MD[> HE82LA$.CII !S)ME"I%\78.:ZLPF(!A.95R=,HB<W<3KN3D+W.?N/<R
MCAR<!-^^9193]\3<V2FXNK==W'P58,"VVXVVDUNS3%7E9:6IA88TRX2JTZTL
M+:-$)V-E6'HG<@Q9F> 9F942(%*D=,1$>1%P/LZNL<+/0<TMF[/,JE#SD/,*
MQ3Y'&Y64HG$RC22/&O3MZ4DX!G(%:BS>"@HDMZ9=7R5$U/"<M;]PM1V#9,CC
MHQBD?=M&EZA]EA2H![G%[R%4SY2,)55B/CY\)@?W]2K[+G?+MAVFU7:SV^[D
MXVS8M@FX[Z7%W+OU.-HT4QC@=;7$K%I9"WF6%$SS$/$SGYCK/OI^X"J&A^C%
M29VLK2NRK.DO,UYYL"Y1!1.TR5?3LEM6?J" F.VIT&T:U=@F0O@)'U]$"E,H
MLJHI2IWDW)ON[N>+%ENUN'S*KHK.XC%-'6<G48T*@%<F/&1R2 "#<9^92*C+
M7&63236E9A44!$(V,BVS;8!;(X/B]D,%Y+P5-V:QT^%R?6UZK+V&I^[?I QB
M7KIJK(HQX2S&1CO]L&2"L4X!RR6+Z%XX!,"+>6J2$(_LX>M)O'X<_P"P9#&
M_A,5OC'Q)F, ]CD[T<0\1!$#%[@(=P#Q (=P'OW;5L_D:&(P.O)2&&H5P]PG
M96B7N5$*KBP2XDQ2 $Z9GD6.?["Y8L2C&?9W[R=L=4V;>.Y/=*]??ONR9-\X
M]Z<1;R0X^C=([>3?6<N#!#+SWKI"$<,K4:$5U2%>TU9UX-1.G%M3NLB\F</4
MJ/;4&-D%XB4R9?)<:O14Y5N5,7D/'/",I29L<FU(L0'[:NPDFA&F4*C*O&"Y
MRI&O?:@XRR-A?6/"&(\L35?L-^QGCR!HLY-55U)O(&13JZ)XB&<L',RPBY)4
M#0+6+*Y%TP;F*\(X(F4Z)4U#]D8@Q53,(8PHF),?1B<13<>5B)JM?9$(D4Y6
M,6U(B+IV=%-(KB2DG +R<L],0%7\F\=O5Q,LN<P]C\D&GZ33U5<N![[&1LU@
M5=81Q%;R\A9((2(QP*SB8 S(V3$E,R,'X#6'?C[0V?[TVQQ[\=C<9JN(RMBY
MKU5=>3RPK);:PNR.08T_-UE!"=BO66BJ!BH(!A(AS'''/EKQ<J[CJFVN_6^2
M1AZI2JY-6NRRS@?"C&P->C7,M+/E![A^Q;,&BZH!W 3&*4A>YC  SH -A@M8
MD;&$(  Q)$9E,"(B,<R1$4Q$1$<S,Q$=:YD0@)&90(@,D1%,0(B,<D13/Q$1
M$3,S/Q$?,]5=/:3=MR,(3%VF=7E4RJSAFV9\P@@JD;R8&'=NF6-*\].DN8Z1
M9&<:S5O>-%T2&%&N0#D!%%R'CDBZ'^HA=9M(JO8++$@SR5L8=MF&[)O$0!VQ
M@I>.3;XWJSDH@!@2BJ49I)O&2Y .VG++/IG 1,(<J\:^5>U=7CJK#:;LQ>K4
M^^9">9;R*S4!<R58P-CQ2/2K])7<(D6!H+R"94['"9SCX59*;?.A,8XK&'8*
M((I-T4D$$DT444R))(HD*FDBDF4")I))D I$TDR 4B9"E I"%*4H   '-B>Z
M)AHFB:CVLJD(Y!Z0V;;B44<G>L3,UZC"#X8*WPR."XF4X[&MB."B>JFTH2V;
M9L]NKQDJJS+#X&"B>!K*@?:\.?V9-4AS$<Q[+=P)GD9ZU\FY>.[ATI^J$>X8
MS8K,8"K7Z'V"PRT1.LS936-+;(OUIO'XJ)D2 T:W4&ZXN>H% Q212;%4X#YZ
M(FOPXIR55,R8TH65Z+(IRM.R-4:_=*T_3.4WGPUCC&THQ\T"F-Y3E%)R#=V@
M<04;NT5T%2E43.4(./:%]2_NRZIQ>PM8C/47K6.3<S<L9JB)WLCB*UJL8^\H
M&*BF99P2LR2%?NA14-Y3&,BK$J7P>I5,;J+V</;@;QAV_:@VN4\VR84>+7G&
MR+EPJHN[Q9<)0XSD6T(<#$*VI-Z=*CX$U !"/N42B1(J2'B'NW2/X1NTNN[V
MO]=G]-*-<V<H_$YU.)2NO<=/[9S#&U+<S$0,'D[\S/BB9CJUWG4=[RNLGR&+
MV ?O;#Q/PM;^#)B%Q^R,> 6*_$S)2-.M'YL'FS'R*WJ2]53#O3ZKK6"78#DS
M/EJBCR5+Q-&R)8U-M&&56:I6Z_3I4'@UBI@[0609%19O9^R.T%FD''&;-Y*6
MC)$<LY'@,/XOR)E>U*"G6L:TBTWN>,50B2@Q-4A'LX^21,<!#SUT&)V[<H%,
M8RZJ92E,80*.OIUCQ3E#J\=0I<^2IR524R7.S.5\TV1@H91>EXNKYV:?T<KI
MURK$CRLVCFMXQI)/*40BE'K:4,W4]&[*K$.TVB8C969S9-L<ROJ&HU(NY05F
M2V7W2#'+HB83#87*D,.Q].46625>LB099%JI!O6S7\0&-P^#6+<]GGS6I28B
M8U5P0 =@A+D)/S: JEL2D8%KF00ID#[X>]3[K#[J6Z69X+F\H$29+N%U*1JQ
MBDONZLMW*2QDVTM9 A+18@.5MXS-UK);4%EU"%<LVZ:P)%+]:3=SKG:4&:W'
M,S7/;FB1ZS4DDGL5BA"XX^>H(IM0*UE+Y$1;63AC+$413-()7N,<G=J'%59T
M\*Z2&[#AS"V+< 8]K^*\.TB"Q_0JPT*TB*Y7VOIVJ?P#SGCU<YE'DO+/E %Q
M)S4LX>2TH[.J[?NUUU#''L9ZP8R+-U'/VC9XP>MUFCQDZ02<,W;5PF9%=LZ:
MK$.@Y;KI'.FL@NFHDJF8Q%"&*80&0VN\VJBXJ%'M)ILZV)>H:]NG7C+.KC/$
M-*\NL85[+!CS\O5:8IA?%EI#[2Q*NWN<)46K.]Y^,O,0R6I>Z:*V3$3(17-T
M&U0S^&(\T"8Q_@0&?"*N&=.JCBGJ$=)[<:#]V$QIGZGXSJTE=<5NI$TFWD(?
M[IM!:GNV/YI1LU/8*D=XJ1!^W<((3U6=+MFLXV,U>Q,O*_&^S _V[=C_ "V
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M[?KNHUL9K/>'2<2BQKC,K7#/:ED(AU.K=6Z9.LU1^\5U'.456S7+V5^'U&U
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MF6@D0<BU>2J1X9G"1UT+$&\U29K%@B6ME<%;J$CY]-^F6.>7>/ 7Z@_'^_\
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M*_\ C_7_ /[@G_\ QQS6SZ6S_P"[O_[%O_@_\\3_ %<V_P#4U_\ GD_]JO\
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MGGM8S5&A<RPY[-,L6;E.O;NIP^U8Y"L8Z'/6;O$OHL@2/$^ E<>,C\=; +K
M,[N/3]SG8\>66W5.UT%.GWQG+4F>G:Y.IQE:NT&I9$RR=>>,) C(U9<2RK],
M5_3*-$5#."B0GC+2&A-M=FZ[.P\^EL)G=ZK7YJ*G4V3G,62'C5\>#DFLH#)R
MT<6=1N[;/19^E<-5TU$'**QT%DSI*'*-[S4'*M3WIT-HDY.+!*H9*Q(_QAEA
MDH9!9TWMC2#<4+)#%TB85RIJ+R"3Z48E7 QEX^0CG8E$C@HC0=V!PA;M;,U9
M)P7=TSELF,;2]K2[L4E$DIJ-1!)U7;,S!4"G,PL]==14^S-V'LE( D8?,24
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M7)=0W?A4$-K.9*2EM=2&H6"!9+7,Z-<H/[C.RV8SV4R X^MDF4J.#I6BJUT
MH%N@GB',G,K:L89'@UC!:9-D8  IRJ]#KJN8[20F,:[GUYW*QZ"9&K2$S[L3
M2':2351L9JU9.7<2ZCP2(*1#IHK&;-4/3)$\)@,4"1(]1:B;_8WNF-ZGO[8Y
M^UVIC2;";%\W/W:IY"4=4U2?3]^>FL]=$95V0)XK;S$K>!9I$!0! I61BAS9
M$B(  B(]@#YCRBO[1'GNFY9W.KN/*:_:RXZ_8Q<4>Y2+-4BZ"%^M$\K:)NN
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M3E.0YB&BH]E_>/\ RMTX\!,:*(\P.^+W\($))*M<I-%!*'DB83J,F[<#B#@
M*5),/($3>9S[#VC3="J-L?U722E33>4N]BLE<R+F)O'NO,"J5*O"I)TFL3()
M>)).9MMA48V0(I90KUE!5]G(NVZ;>=BE'&2OLZ^NLUB?3JS9@LL>YC9/9"_%
MMM?1<'+XG.-:?$EJ]-E?(!0QD"3<D>VS#(54DE742]C'@"HU<-1#9&NAVO\
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M^)F.=[B)XGCF/&I/$_TQS$3Q/[XB?SB.OC(C^&%'Q^6M%,?U3PR.8_ZIF/\
M),]6'.8)=3S[WGN;^3EE/^C+OF=O,$NI[][SW-_)RRG_ $9=\I36/Y2Z]_;F
M)_O]?JQ<Y_ZFRW]FWO[LWJMM[,NV;FV.V>>&13,Z;X2I+9!P)0%5)N]R*^4=
MHIG^94W)V#(ZQ ^!S-41-W$@<N;<IG^S*_NAMH_^9F@?K"F>7,.6C]H7^=+-
M_P":87_N>E\?Y.9F>/Z9F?WSU#>U/\BL=_G&1_OK^O!0I3D,0Y2G(?L0Y#E
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MUC^4ND8B[9<$G*!TUT4SEUYVVW2UV7P!M=,:Z8[QEDC-,=/"YLN&[)3JM*V
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M4K;)G7+.+AICJ^/:X2,D;$2'87)"2CJ^\C'L56[FPA;.SEFRSIK]%GDPJW<
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M91<%:I^G*2TE:1CR'?R2)DR%<R!J9#O71RJJO_4O%%')KO0@ _/_ %_#^/\
M#SY^3J=8FURN9FNP<LX(F")'$I$1TBN5(!$P)E6>M5U03\0B;P ?P@(B(!WY
M[:'=^G>P6.U_?],QV[(PZHKXO(,OV,3E:U<0!8J9=KI>UG"U*61I*L3A4H[,
M6'![9\UK0+%;)VLIJVPV]<9?9+;M4*R[M)K9*2DQ0UJ@"/(C,08+H7+&0CU
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M @X--5*%AXN(27."BR<7'LXY-90"@0#K$9(H$5,!  H"H!A H '?L !SVPE
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GXXZ=.....G3CCCCITXXXXZ=.....G3CCCCITXXXXZ=.....G7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g85507.jpg
<DESCRIPTION>G85507.JPG
<TEXT>
begin 644 g85507.jpg
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M:OE/0XB4[ \Q[[>MJL#+'AI(D"Y2*#K(*]M>X(JLQ**O^Y18VF92L7[*T<F
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$?G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g970489.jpg
<DESCRIPTION>G970489.JPG
<TEXT>
begin 644 g970489.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!!35),3%]'4D%02$E#4SI;041!4%1)
M34U53D5?3$E-251%1%U-05E%4E]"4D]73E],3TY?2U]&3T]415(N15!3_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  "P@ 9@*7 0$1 /_$ !X   (" P$!
M 0$            '!@@!! 4) P(*_\0 /Q   @(" @$"! 0$!0,"! < !08$
M!P,( 0() !$5%B$Q$Q0741)!88$8<9&A\!DBL24R8L'1\2,D)G*"DN'_V@ (
M 0$  #\ _OX]'H]'H]'H]'H]>:VZAK8<!>^EZ[4FP$FL%+82ZRM(. 'I559.
M^2!@ Z_;#7KW;PAAP$3B,8T1G56!5L\#/WE!< 7.0EQH&,MEQR^E,EKR@6\.
M/H5=6PF8!&>S]V+QJVJ;,22BD4[-]<4CY(0^IK O/*"= #8=?<XUM^2(D5L&
M-+,98<8YI8\^%'(]!N.:Z(GDQ*6#IIMU>4JO"]'/6O*,):\Z5R1ZME@"0[<L
M1V-5-%E.QZZKO#AD3OPRT463A!G.GWG ,S'JJM.R5OM\5PV2H+>3'<5Z7S2[
M-6WZ5Y*AQN1A=)LC;,ZE; 2D6RF&MC;[ %FT926)B;DF"1A..VUB_P!O)X/@
M[@4[$94.Q1I1.CU7!>4AAM[7O?EJ4JQPUK8&LVF?.TE;G)!8Z]I3HN6!6]Z,
M%7'X4MFK2L![-'CG*9(92)%%[V#3[:(FC2->6V[B)4F9'BN?S-PER0V#".OC
M^TC%3(=K00^"L#B!"-5_)>.J01Q=8IINJH=<(=>''FR^@<(\!;.L4V+@"LQM
MOKI7$DP.4C]V?S,?(W)2*V:]1N#-<7FXT[>(9/MPJ^S$X<I7]7=!_J$J?+U*
M9.""J;,/<@R&+W5QKNK3NJV63H3=,L2.05A3GI_>6U9^H6B3G/1%^V-D=O(6
M0('!=V/K3E<=V-8K.QK;>CC W851[Z* 6&H5J9Z!H,)7.3RQ^6*@?E8 GDT?
M"J QYE\ Y."V%!URDFE&RV)ZK^C\@NZE(F:=+(J>ZJNH:RA3AP"6#:6CI>)W
ML65)KVQ0#U9(E^6UK@QF'JW9L4(A7[<>79UBEPR>:U0PCWEUL0A4%>#HE_"R
M*V:L5+WN#^/VT.K$Q_I7$(*Z.O6V>'M"BRQEAC872N\!6>01TQGC#E<MUM>_
M,##N>T**K!DUZ*U].V#%PV),)Q[0#.$0:MX@6WWS'-9\6-17.T$@/=M.W$.$
M'#<I>.:36U5<RA-9-X3Z *5C!YI,IVI"5@@*+-J*8<J9&EC7_I82LP-JS:5T
M>.QHW\1!PZNR*;T7&4 N*8#*J,+&;;A.#NUYPF6&I'%R8<SA'M$\H)CLBXGR
M%3J[/36)R+4_3AAGNX2LV';%JH-FI]06#!E44NULWVC'&_-!EB)*,.EE:^GY
MC$+N#-,K55Y:E;!-JO\ ]:)IF85JYVJKI-=Z\8A-;,1 6MRL;G;TM@BK_D8Z
MW(CF +6I*F# MQSFELOA..P<RL\=,F 3RR+H/"T,@I+>-@^79PK0JY(3!JU
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MWR"U?1@M+M+CKO5:C:..E9 44&@HE3PG<,@KL D=QI")'5[-KU9< !\>H=A
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MA-ES,W\<B1FR=YKZ/1Z/1Z/1Z/1Z/1Z/1Z/1Z/1Z/7Y[=?XN/;W]O^[KV_\
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MMSQS[^W/'/K]>L>_'_..??\ T^_M_7[>CWXX_P#'_P _K^W]_P"G[\>L^_\
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M Y7V+8FR>L-FLNL#)V.XD6OR%6?R[KCT2 :R&1O>EP&I4ZOG&JG7-:M!K$?
MV-90!9K],0X56+NU <O+U& BG&0S[!%#4"LIEP2$.?1-01PQFQ\V[T*NH-(E
M<(ZH8++A2XFK4>0W9@PPT/L.3P0DOG9WQ8\$&'%7K>\^2.T&VQH[%$W'7ZA5
M'RJGT?#%U )).L$^!VCL1+8ZSZ" FLP$$WHLNH"R*;=%%*G[()LH 'CM<2]F
M45*;L??K8K9\IZ-2L<#7B3= *\$[7T"+4:7&:ZK_ &H +6 ?QQ"VJ#8 @_\
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MFU?:N,M& V4E5D>QK*E+]='9*M-DD?R]>$#RB.J:E-@:Q4!FMRTJE&WW;]R
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M2+;-9GK.;G"*T6(5-UVFF%9DAZ[YME2>NU:N9^G076VL:W=4LN)/9[+I&78
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M,'P+L$2-K.!73>.>&L,QSVG@SL2W2%V!(>)]'K\5)'AN]9$G/=5/WN[S&IB
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M7&&<2EQ8W?K&Q8._%8'#PR"7]BMAM;=HK5FMSTLM*LHO<8+"[/B/A.[-*FS
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M^D0K5*]O(V\W'3#%=ZX\KZ!8EHF:WL"L9U#Q593KM/A: 5;>L.RL;-F7N'R
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MX@0H?,%&<#2/^67R,.G%E].MI:^K[A6U2-FQ#)9#+*DJN-FU_8Z,LS5JJ#;
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MCR!Y@W1Y"**MR"EIUK:7Q+M6K;M#"'U'&OV6MF4+:9<+LLMZCG7 ^+< LO\
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M$[11*OKG#L4DCEZ&[7:)70C69BOJ@82N5TY#P$S B<ZD*UAG% P2'=B;'UK
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MOU.2K%QKZF2^(2A40+,YEF%M\1V>6B9_B&H> K9G,M)2\4^,HCSIKB!LUUL
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M8A<W%ALJS^0O1M)G\BF7:NB1!+E5%/7$'-8B_DDYE=A5X#T!,X,423([2L+
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MQ8N8T/'Q5UA\1@,S>K!;??8A][KK)M:C;=YZU(+^*8&7;&KJYE6YQ@M-YBM
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MWN?1)1SZFR-4^7QAZKTB\<]W=FS@2)[&.I?/N1WW#[!/AW;GD=V'\,_?E/\
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M&Q;_ /H(!@<GB*=#252.Y&;:E:42-)R5AX+#DRY_P45E2L(=['H&!6F"83Q
MF1I1(HF$^BN/<9GQ5#K"G[ O-M7\QM]N[-T!LC0]JNH!  )B_P!Q=\5WKI5<
M$VI(O4R?PKV>OD[71=ZQ($H^:^:CC*QDC9#%"P@1 EN;5:$1M@[>J^Y1[TC
MV&N*:?:5PA+1U[1=@E B">FJNVZ2<C 7,N'Q V2!/KH=#Q3X>7-UDBB)&'FQ
M=>>V++TVA>E%BJME'B]?;2M->U/8EJ!+_M6K%:NUZ(::KA'CE;X_W 6GW-=V
M!+J:S#B0$-6=6. 4:)FXF=A4URP%%38R GA#B/%/V94V*G7ML<:NB1ULUTMQ
MB?,]5KBC9%B/S[KQ>FOI5EL5GCL9["<(@ MP"R5<QA E=7JV@5@DI2@OC5*)
MT'Q7K1F@72@D^[AR3?\ 9,>P[KK>HULU<G 1-[/ ^QJS330DM=?Y4@+*+)AR
MLEU8CMCN0PH%RKV0N7GAX$*.'R8<<=1K?B-I8W,Z9;Z8>;<"2YM^-1>M5-9D
MT+4&!_V&&5^D/;"FI%:-^":IALE8(69+Y5L[*PXC\ZQK;=7$JR,C^0S1VAJW
MXX*NUGF.5D?CK=R;(',*K'7]D;(K!"XMY9@HVN-::W+@2$[Q1,UBPBY"G60T
MBQ8HL_!%,%C[1ERCOP"LB/EZ6QVE3)LVFZHRK&LE)QVSKL6[N)HP9I-6M2KG
MYX8J29:C=Y4NKVX@+'1!<C,W&F17XZ3.) *;B'8_P\V+'EQ]D58/B@4+$6'/
M"UV!R=*.,K7\R<7E94#TVB%,^O-)V13855!0EGHTR*S5G$&_2.9N5?BG,R5E
MB8I"V,FXNG [M235/Q\/&TRW8=^/&Q34ELYC+WJZO3B0+"8&$5%KC7=9UD9L
MC-G!AT3'Q!)&5@Q]$V0ML1U1GD9XUGK<ZPAAE;6V7?#178H1:\65=3;)(V_
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?<0^&2,^,Q/G35@FT32N;\#)UDL>01@CXQPF#SV__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
